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Abstract 
 
 
 
 
This dissertation primarily describes chemical-scale studies of nicotinic 
acetylcholine receptors (nAChRs) in order to better understand ligand-receptor selectivity 
and allosteric modulation influences during receptor activation. Electrophysiology 
coupled with canonical and non-canonical amino acids mutagenesis is used to probe 
subtle changes in receptor function. 
 The first half of this dissertation focuses on differential agonist selectivity of 
"4#2-containing nAChRs. The "4#2 nAChR can assemble in alternative stoichiometries 
as well as assemble with other accessory subunits. Chapter 2 identifies key structural 
residues that dictate binding and activation of three stoichiometry-dependent "4#2 
receptor ligands: sazetidine-A, cytisine, and NS9283. These do not follow previously 
suggested hydrogen-bonding patterns of selectivity. Instead, three residues on the 
complementary subunit strongly influence binding ability of a ligand and receptor 
activation. Chapter 3 involves isolation of a "5"4#2 receptor-enriched population to test 
for a potential alternative agonist binding location at the "5-"4 interface. Results 
strongly suggest that agonist occupation of this site is not necessary for receptor 
activation and that the "5 subunit only incorporates at the accessory subunit location. 
 The second half of this dissertation seeks to identify residue interactions with 
positive allosteric modulators (PAMs) of the "7 nAChR. Chapter 4 focuses on methods 
development to study loss of potentiation of Type I PAMs, which indicate residues vital 
$"""!
to propagation of PAM effects and/or binding. Chapter 5 investigates "7 receptor 
modulation by a Type II PAM (PNU-120596). These results show that PNU-120596 does 
not alter the agonist binding site, thus is relegated to influencing only the gating 
component of activation. From this, we were able to map a potential network of residues 
from the agonist binding site to the proposed PNU-120596 binding site that are essential 
for receptor potentiation.!
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Chapter 1 
 
 
Introduction 
 
 
 
 
1.1 Neuronal Communication 
 The brain is the most complex organ on earth. There are approximately 1011 
neurons that can make upwards of 104 connections each, comprising a total of perhaps 
1015 junctions for inter-neuron communication. Neuronal signaling requires propagation 
of an electrical signal between these individual nerve cells. An action potential (electrical 
signal) travels through the axon of the nerve cell to the synapse, which is the junction 
between two neurons. Once the electrical signal reaches the synapse, vesicles containing 
small molecule neurotransmitters fuse to the cell membrane and release the chemical 
signaling molecules into the synaptic cleft (space between two nerve cells). 
Neurotransmitters diffuse across and bind to integral membrane proteins located on the 
adjacent neuron. The binding of these molecules triggers conformational changes in 
proteins that allow ions to flow across the membrane and regenerate the electrical signal 
in the adjacent neuron for further signal propagation (Figure 1.1). Synaptic transmission 
is the basis for neuronal cell communication, which is responsible for a wide array of 
processing that varies from sensation to learning and memory. When these processes 
become faulty or even fail, debilitating health disorders can arise that range from chronic 
pain to neurological disease. In the Dougherty lab, we seek to understand the functional 
&!
properties of the proteins responsible for the continuation of the electrical signal at the 
synapse. 
 
Figure 1.1 Neuronal communication through synaptic transmission. (A) A diagram of 
two adjacent nerve cells with close physical contact at the synapse. (B) The synapse is 
the space between neurons where neurotransmitters are released to diffuse across for 
adjacent receptor activation. (C) LGICs undergo conformational rearrangement upon 
neurotransmitter binding to allow ions to traverse the membrane.  !
1.2 Ligand Gated Ion Channels: Nicotinic Acetylcholine Receptors 
 One class of proteins responsible for neurotransmitter recognition is the ligand 
gated ion channels (LGICs) or, more specifically for this dissertation, the Cys-loop 
superfamily of LIGCs. The Cys-loop superfamily comprises receptors that are both 
excitatory and inhibitory. The cation-permeable channels, nicotinic acetylcholine 
receptors (nAChRs) and serotonin (5-HT3A) receptors, are excitatory and responsible for 
signal propagation. In contrast are the anion-permeable channels, GABAA, GABAC, 
glycine, and GluCl receptors, which are inhibitory and responsible for signal termination. 
Cys-loop receptors are comprised of five subunits that can be homomeric (identical) or 
heteromeric (two to four subunits). Each subunit contains a large extracellular domain, 
four transmembrane "-helices (M1-M4), and a variable intracellular domain 
'!
(Figure 1.2). These arrange in a pentameric fashion for ion permeation with the M2 
"-helix lining the pore. Neurotransmitters bind at the interface of two subunits and cause 
a conformational rearrangement approximately 60 Å away at the receptor gate. The 
“gating region” comprises several residues along the M2 "-helix that are responsible for 
ion permeation. This dissertation focuses mainly on the nAChRs and their 
structure-function relationships.  
 nAChRs are aptly named for both their natural agonist (acetylcholine) and for 
their sensitivity to nicotine, the main addictive component in cigarettes. These receptors 
are responsible for synaptic transmission in both the peripheral and central nervous 
systems (1-3). There are 17 nAChR subunits: "1-"10, #1-#4, $, %, and &. However, "8 is 
only found in avian species and the “muscle-type” nAChR ("12#1$ %/&) is relegated to 
 
 
Figure 1.2 Structural arrangements for Cys-loop receptors. (A) A representation of a 
single subunit depicting the homologous regions for the Cys-loop family. (B) Examples 
of hetero- and homo-pentamer arrangements for the nAChR family. (C) Crystal structure 
of the mouse 5HT3A (serotonin) receptor (PDB ID: 4PIR). 
(!
only the peripheral system and neuromuscular junctions. "2-"7, "9, "10, and #2-#4 
comprise the neuronal nAChR subunits and are prominent throughout the central nervous 
system in varying assemblies and distributions (Figure 1.2) (2,4). Due to their vast 
presence, nAChRs are crucial in memory and learning and are prominent targets in 
neurological disorders such as addiction, Alzheimer’s disease and Parkinson’s disease 
(2,5-10). The most abundant and widely distributed receptors are the "4#2 and "7 
nAChRs (3,4). The "4#2 receptor is a highly sought-after drug target due to its role in 
nicotine addiction, as seen with Pfizer’s engineered smoking cessation drug Chantix® 
(varenicline) (3,4,11,12). The "4#2 receptor has the ability to assemble into two 
stoichiometries, the high sensitivity ("4#2)2(#2), and low sensitivity ("4#2)2("4). In 
addition, association with other subunits, such as "5, has been seen (9,13-15). The 
accessory subunit (the unpaired 5th subunit) can provide distinct tuning of the receptor’s 
physical properties. The "7 nAChR is a homopentameric channel and also widely 
distributed throughout the central nervous system. It has been a constant drug target – 
both in agonist and allosteric modulator development – due to its association with 
neurological disorders such as schizophrenia and Alzheimer’s disease (16-23). 
 nAChRs are large integral membrane bound proteins, which makes them difficult 
to crystallize. However, crystallographic success has increased and generated valuable 
structural information over the years. First, high-resolution crystal structures of a 
homologous soluble acetylcholine binding protein (AChBP) and a low-resolution 
cryo-EM structure of an nAChR provide useful information (24-26). Several years later, 
high-resolution structures of homologous prokaryotic and invertebrate LGICs were 
obtained and allowed comparisons to be made in what is thought to be the resting 
)!
(closed) and conducting (open) form of an ion channel (27-31). In the last year, an 
exciting breakthrough occurred in that the first set of high-resolution crystal structures of 
vertebrate Cys-loop receptors (5HT3A and GABAA) were achieved (Figure 1.2) (32,33). 
Although these advances have influenced our structural knowledge, proteins are 
inherently dynamic, and static representations may not accurately capture motions 
associated with activation. Thus, structure-function studies still provide vital information 
regarding interactions necessary for ligand binding and conformational rearrangements 
required for receptor activation.  
 
1.3 Non-Canonical Amino Acid Mutagenesis 
 The goal of the Dougherty lab is to use physical organic chemistry to provide 
chemical scale structure-function relationships. By identifying distinct non-covalent 
interactions – cation-', hydrogen bonding, van der Waals, etc. – we can elucidate 
contacts that are critical for receptor function, and begin to map important properties to 
ligand recognition (pharmacophore identification) or functional coupling (conformational 
motions) on a large and complex protein. We can have a better understanding of 
neurological diseases and compounds designed for treatment through increased 
knowledge of the mechanisms associated with receptor activation. 
 In order to study chemical scale interactions between a ligand and a protein, 
subtle perturbations must be introduced and the effects must monitored. Conventional 
mutagenesis is limited to the 20 naturally occurring amino acids. These provide a good 
starting point for identifying functionally relevant residues; however the structural 
changes between the side chain groups are quite large and do not afford the delicate 
*!
functional distinctions that we aim to tease out. To work around these limitations, the 
Dougherty lab has established a working protocol to incorporate non-canonical amino 
acids that has proven to be a powerful technique in studying structure-function 
relationships in LGICs (Figure 1.3) (34-38). This opens the possibility of probing 
interactions through the introduction of diverse side chain configurations to study specific 
interactions of a protein on a chemical scale. 
 The Dougherty lab has utilized and optimized a method known as in vivo 
nonsense suppression to incorporate non-canonical amino acids (Figure 1.4) (35,39-43). 
This technique allows for site-specific incorporation of a non-canonical amino acid in a 
relatively quick timeframe. The mRNA codon of the residue to be probed is replaced 
with a stop or “nonsense” codon (UAG, UGA, or UAA), which is normally used to 
signify protein synthesis termination. The non-canonical amino acid is chemically 
 
 
Figure 1.3 The power of non-canonical amino acid mutagenesis. Conventional 
mutagenesis of phenylalanine (Phe) is limited in structural perturbation and lacks specific 
control. Non-canonical amino acid allows specific changes in order to answer questions 
that pertain to steric (cyclohexylalanine) and electrostatic interactions (fluoro-Phe series). 
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appended to a suppressor tRNA with the appropriate “stop” anticodon. Normally, the 
nonsense codon generates a truncated protein that is non-functional and is shuttled into 
degradation pathways. However, in the presence of the chemically ligated suppressor 
tRNA, protein synthesis continues normally until the full-length protein is generated. 
Essentially, the ribosome and the remaining machinery of the cell are “hijacked” to 
synthesize, fold, and post-translationally modify the desired functional protein with a 
non-canonical amino acid. Xenopus laevis oocytes provide an excellent system for this 
method due to the extremely large (1 mm in diameter) single cells and the minimal 
expression of endogenous ion channels. The oocytes are large enough to allow direct 
injection of the suppressor tRNA/mRNA mixture and contain the cell machinery for 
proper protein synthesis, folding, assembly, and transport to the membrane (Figure 1.5). 
The physiology of the expressed ion channels is nearly identical to that of those 
expressed in other cell systems or found in native neuronal environments (35). 
 
Figure 1.4 Depiction of nonsense suppression methodologies used for site-specific 
incorporation of non-canonical amino acids. 
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 Since evolution of a tRNA synthetase is not needed in this method, incorporation 
of new non-canonical amino acids can be immediately swapped to probe a large array of 
side chains. The downside to the in vivo nonsense suppression is the small amount of 
protein that is actually synthesized. Theoretically, the amount of chemically ligated 
suppressor tRNA injected translates to the amount of protein synthesized, if efficiency is 
100%. Because of reagent limitation and inherent efficiency losses, however, only 
attomoles of the protein are generated and this is not useful for studying by many of the 
spectroscopic techniques available. To work around this extremely low yield of protein, 
we turn to an equally sensitive technique – electrophysiology. 
 Electrophysiology techniques can be used to indirectly measure receptor-activated 
currents. Again, the Xenopus oocyte provides an ideal system for electrophysiology  
 
Figure 1.5 Schematic representation of nonsense suppression methodology in Xenopus 
oocytes for non-canonical amino acid incorporation into ion channels. (A) mRNA with 
incorporated stop codon at site of interest. (B) Chemically appended non-canonical 
amino acid on orthogonal tRNA with an appropriate anticodon. (C) Physical injection 
into oocyte cell. (D) Expression of ion channels containing a non-canonical amino acid. 
(E) Electrophysiology output assay.  
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Figure 1.6 The EC50 experiment. (A) Increasing concentration of an agonist shifts more 
channels to the open state and creates a larger correction current for the TEVC 
configuration. (B) Responses are normalized to the highest response and plotted against 
agonist concentration. Fitting the curve to the Hill equation generates a value used for 
functional comparison of mutated receptors – the EC50. Gain-of-function mutations are 
depicted as a leftward shift, which decreases the EC50 value. Loss-of-function mutations 
show the opposite trend: a rightward shift represents an increase in EC50 value. 
studies because its large single cell size allows direct electrode attachments and easy 
integration into an electrical circuit. The two-electrode voltage clamp (TEVC) method 
allows measurements of membrane voltage changes induced from the activated receptors 
(Figure 1.5 and 1.6). In this method, the voltage electrode monitors the membrane 
potential and the current electrode provides current to maintain the desired membrane 
potential. Upon channel opening, the membrane potential changes and requires additional 
current to maintain its constant voltage. This injected current is directly related to the sum 
of the currents passing through all the open ion channels on the cell membrane. The 
sensitivity of this technique allows current measurements of tens of nA to µA during 
whole cell recording. Electrophysiology requires only a small amount of protein for 
signal responses and provides an extremely powerful tool to measure the influences of 
subtle chemical perturbations on receptor function. 
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1.4 Electrophysiology Assays: The EC50 and Voltage Jump Experiments 
 For the purpose of this dissertation, two types of electrophysiology functional 
assays must be discussed – the EC50 and the voltage jump. The function of the receptor 
(wild type or mutant) is assayed by applying doses containing increasing concentrations 
of agonist. For simplicity, receptors are either opened or closed and remain in 
equilibrium. With addition of agonist, the equilibrium is shifted towards the open state. 
Thus, higher concentrations of agonist produce a larger population of open receptors and 
a larger current is measured. At sufficiently high doses, saturation is reached and the 
response levels off. Measurements are normalized to the max response and plotted in a 
logarithmic form with agonist concentration. These data are then fit to the Hill equation, 
which generates an EC50 value and a Hill coefficient (Figure 1.6). EC50 is the 
concentration of agonist needed to elicit half-maximal response from the receptor and the 
Hill coefficient is a measure of cooperativity. EC50 values are commonly used for 
functional comparisons: increases in EC50 values correspond to a loss-of-function (more 
agonist is needed to open the same number of channels) and decreases in EC50 values 
correspond to a gain-of-function (less agonist is needed to open the same number of 
channels). The EC50 is a composite measurement of the agonist binding and the channel 
gating events. Mutations near the agonist binding site are assumed to influence only the 
binding event, while those close to the pore are thought to mostly influence the gating 
event; however there are exceptions that are discussed later in this dissertation. For most 
of the experiments performed here, the EC50 value provides a functional measurement for 
comparison of the wild type receptor and mutant that is being introduced.  
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 Another electrophysiology test that provides information on receptor properties 
involves the voltage jump experiment. While the ion channel is open, the negative 
voltage potential across the membrane drives the flow of cations into the cell. Since we 
control the membrane potential of the cell, we can vary the voltage by quickly 
(ms timescale) “jumping” the voltage from large negative potentials to large positive 
potentials. Switching the membrane potential from negative to positive then drives the 
flow of ions in the opposite direction – out of the cell. In an idealized pore, plotting 
voltage vs. current would then provide a linear relationship (Figure 1.7). However, not 
all receptors act as free flowing pores, and they have a unique property of not allowing 
ions to flow out of the cell, which is termed inward rectification. The degree of inward 
rectification can vary between receptor types and in some cases can be used to distinguish 
stoichiometries of specific subtypes (44,45).  !
1.5 Mutant Cycle Analyses  
 Proteins are comprised of an array of interactions that work in concert. 
EC50 values are useful in interpreting the influences mutations have on receptor function, 
but they alone do not identify the strengths associated with these networks of interactions. 
The mutant cycle analysis provides a quantitative measurement of the energetic coupling 
of intermolecular and intramolecular interactions occurring in the protein (46). This 
analysis has been employed in numerous studies of Cys-loop receptors and has provided 
valuable information about strengths of interactions (47-55). Mutant cycle analyses 
require three values: a functional output (in this case EC50) of the two single mutations, 
and the output of the collective double mutant. If the mutations are functionally coupled, 
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mutating one of the residues will change all or most of the interaction in question and 
perturbation of the second residue should not cause any additional change in function. 
Thus, the sum of the functional change of the two individual mutations will be different 
to the collective double mutation. If the mutations are not functionally coupled and are 
independent of one another, then the collective double mutant and the sums of the 
individual residues will be identical. EC50 values are used to calculate the coupling 
coefficient ((), which is converted into a free energy value of ))G (Figure 1.8) (46). 
We identify functionally coupled residues or interactions as having values of ))G greater 
than 0.5 kcal/mol.  
 
Figure 1.7 The voltage jump experiment. (A) An example of a typical timescale and 
waveform for the EC50 experiment. The voltage jump experiment utilizes the activated 
equilibrium region at the peak of the agonist response. (B) Voltage is varied on the 
millisecond timescale and the current is recorded for each voltage step. (C) At negative 
voltages, the current-voltage relationship responds in linear fashion (blue). At positive 
voltages, this trend can either continue (green) or be inhibited (red). The phenomenon of 
current inhibition at positive voltages is called inward rectification. (D) A pictorial 
description of the voltage jump experiment interpretation.  
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Figure 1.8 The mutant cycle analysis. (A) Equations used to generate coupling 
coefficients (() and ))G values. (B) Examples of “uncoupled” and “coupled” 
interactions. R is the ideal gas constant and room temperature (25°C) was used for T.  
 
1.6 Orthosteric vs. Allosteric  
 Discussions of ion channels so far have revolved around the notion that an agonist 
binds and then the channel gate opens. The location a ligand can occupy and from which 
it can cause activation of the protein is termed the orthosteric site. Agonists are a class of 
ligands that activate the receptor by occupying the orthosteric site, whereas antagonists 
inhibit receptor function by occupying the same orthosteric site without activation. 
Research involving the orthosteric site has been crucial in developing agonists and 
antagonists that are selective and potent for a vast array of targets. However, another 
class of ligands has been garnering more attention and resources in attempts to develop 
novel compounds for diseases – allosteric modulators. 
 Allosteric modulators are ligands that bind at distinct locations away from the 
orthosteric site in the protein and modulate function without direct activation. The 
allosteric site can be adjacent to the orthosteric site or tens of angstroms away in the 
protein. These molecules are analogous to agonists and antagonists in that they can 
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positively modulate (increase function) or negatively modulate (decrease function) the 
protein’s activity. Allosteric modulator properties are desirable as drug discovery targets 
because they can have high specificity and activity while minimizing adverse side effects 
from off–target interactions. Thus, more research has been directed towards the 
development and understanding of both positive and negative allosteric modulators for 
disease treatments, including neurological disorders. 
 
1.7 Summary of Dissertation Work 
 In this dissertation, canonical and non-canonical amino acid mutagenesis was 
used to study structure-function relationships associated with agonists and allosteric 
modulators of nAChRs. Group methodology of nonsense suppression in Xenopus 
oocytes, along with electrophysiological assays, was used to assess functional changes 
associated with receptor mutations. The "4#2 and the "4#2"5 nAChRs were targeted for 
agonist selectivity studies. The "7 receptor was used to probe allosteric modulator 
binding and influence on receptor activation. 
 Chapter 2 details research investigating the interactions involved in the 
stoichiometry selective compounds of "4#2 receptors: sazetidine-A, cytisine, and 
NS9283. Non-canonical amino acid mutagenesis showed that the previously proposed 
change in hydrogen bonding strengths were not the cause of the selectivity. Instead, the 
residue composition on the complementary subunit strongly influenced agonist 
occupation at the binding site. It was concluded that occupation of all primary 
"4 subunits was needed for full receptor activation and that contemporary binding 
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models should incorporate the influence of the complementary side for receptor 
specificity. 
 Chapter 3 describes the work done towards producing a pure population of the 
"4#2"5 receptor and subsequent tests for agonist binding at the "5-"4 interface. 
Generation of the "4#2"5 receptor was aided through the addition of a gain-of-function 
pore mutation, which also incorporated a handle for identifying assembly through voltage 
jump experiments. Mutations of the "5 aromatic box residues resulted in no change to 
receptor function. This suggests agonist occupation at the "5-"4 interface is not 
necessary for activation as is seen with the "4-"4 interface. In addition, this shows that 
the "5 subunit does not replace "4 or #2 subunits and is relegated exclusively to the 
auxiliary position. 
 Chapters 4 and 5 are dedicated to studying positive allosteric modulators of 
"7 receptors. Chapter 4 involves assay development for functional screening of allosteric 
modulators and adaption of a cooling apparatus for varied temperature control. Chapter 5 
revolves around probing the global effects of PNU-120596 on the "7 receptor. It was 
shown that the higher potency of acetylcholine in the presence of PNU-120596 is not due 
to an altered agonist binding site. In addition, several residues were identified in the 
gating interface that are vital to transmitting the effects of PNU-120596. These results 
suggest a global propagation through several key residues that influence the receptor 
gating equilibrium while leaving the agonist binding site unperturbed. 
 Short appendices are included for two additional studies. Appendix 1 involves 
probing the autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) mutation 
located in the #2 subunit and its effects on "4#2 and "4#2"5 nAChRs (in collaboration 
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with Dr. Weston Nichols of the Lester Group). Appendix 2 comprises a LGIC screen of 
synthesized physostigmine analogs (in collaboration with Dr. Lindsay Repka of the 
Reisman Group and Dr. Kristina Daeffler of the Dougherty Group) for agonist or 
allosteric modulator effects. 
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Selective Ligand Behaviors Provide New Insights into  
Agonist Activation of Nicotinic Acetylcholine Receptors* 
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2.1 Abstract 
 Nicotinic acetylcholine receptors are a diverse set of ion channels that are 
essential to everyday brain function. Contemporary research studies selective activation 
of individual subtypes of receptors, with the hope of increasing our understanding of 
behavioral responses and neurodegenerative diseases. Here, we aim to expand current 
binding models to help explain the specificity seen among three activators of "4#2 
receptors: sazetidine-A, cytisine, and NS9283. Through mutational analysis, we can 
interchange the activation profiles of the stoichiometry-selective compounds sazetidine-A 
and cytisine. In addition, mutations render NS9283 – currently identified as a positive 
allosteric modulator – into an agonist. These results lead to two conclusions: 
(1) occupation at each primary face of an " subunit is needed to activate the channel and 
(2) the complementary face of the adjacent subunit dictates the binding ability of the 
agonist. 
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2.2 Introduction 
 Nicotinic acetylcholine receptors (nAChRs) are a diverse family of the larger 
Cys-loop superfamily of ligand gated ion channels (LIGCs). These channels are found 
throughout the brain and CNS and play vital roles in the chemical and electrical 
communication between neurons, contributing to memory, learning, and other neural 
functions (1-3). Because of their diverse properties and widespread distribution 
throughout the brain, these LGICs are prominent targets in neurological disorders, such 
as drug addiction, Alzheimer’s disease, and Parkinson’s disease (4,5).  
 Neuronal nAChRs have been extensively studied, and much is known about their 
assembly and structure (2,6-8). There are two classes of subunits, identified as "2 – "9 
and #2 – #4, which assemble into homomeric (" only) or heteromeric (" and #) channels 
consisting of five subunits in total (9). For each subunit, there is a main agonist binding 
pocket, denoted as the primary (+) face, which includes four of the five residues that 
make up the canonical “aromatic box” (10). The fifth aromatic box residue and other key 
binding residues, including backbone contacts, are found on the complementary (–) face 
of the adjacent subunit (10). The five subunits then arrange in an alternating + and – 
fashion to form a functional receptor (Figure 2.1). For decades it has been assumed that 
the (+) face of the agonist binding site is provided by " subunits and the (–) face by 
# subunits. However, recent evidence establishes the ability of " subunits to also 
contribute to the (–) face.  
The core pharmacophore of a cationic nitrogen and a hydrogen bond acceptor for 
agonists of the nAChR was first introduced in 1970 (11). Since then, the binding model 
has evolved to consist of three specific interactions that include a cation-' interaction on 
&'!
the primary subunit, along with hydrogen bonding interactions on both the primary and 
complementary subunits (12,13). Based on this model, a number of studies have aimed to 
explain the efficacies and selectivities of agonists to different nAChRs of varying 
subunits and stoichiometries (12-14). 
 Here, we studied the activation profiles of "4#2 receptors and their responses to 
mutations for the following compounds: sazetidine-A, cytisine, and NS9283 (Figure 2.1). 
Our conclusions lead us to propose an expansion of the published structural 
models (10,12,15,16). We establish that: (1) the selectivity of drug binding at subunit 
interfaces is largely controlled by a pocket on the complementary subunit that is 
A B 
   
  
C 
 
 
Figure 2.1 (A) View from the extracellular side of the high affinity (A2B3) and low 
affinity (A3B2) "4#2 receptors. Agonist binding locations are indicated by smaller 
circles at the interfaces of "4-#2 subunits and "4-"4 subunits. (B) Sequence alignment of 
the rat muscle and neuronal nAChR subunits. The three residues that greatly influence 
agonist affinity are highlighted in gray. (C) Structures of sazetidine-A, cytisine, and 
NS9283. 
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hydrophobic in some subunits and hydrophilic in others and (2) an agonist must be bound 
at all " subunits in a given receptor to favor the activated channel. This expansion aids in 
our understanding of subunit- and stoichiometry-selective agents and can provide 
valuable insight for further development and application towards therapeutic strategies. 
 
2.3 Results and Discussion 
2.3.1 Hydrogen Bonding: Non-Canonical Amino Acid Analysis 
Sazetidine-A has a unique activation profile, in that it selectively activates the 
("4)2(#2)3 stoichiometry over the ("4)3(#2)2; these stoichiometries will be abbreviated 
A2B3 and A3B2, respectively (17). Unnatural amino acids are useful tools used to parse 
out specific chemical interactions between ligand and receptor. Previous structure-
function studies of cytisine, an agonist that has the opposite activation profile for "4#2 
receptors, showed that the active drug-receptor combination (A3B2) favored the 
hydrogen bond to the TrpB backbone CO (“donor”), while the inactive form favored the 
hydrogen bond to the backbone NH on the complementary face (“acceptor”) (Table 2.1, 
Figure 2.2) (12). We proposed that this difference could explain the stoichiometric 
selectivity of the drug. Through unnatural amino acid incorporation, we were able to 
characterize the cation-' binding, hydrogen-bond donating, and hydrogen-bond accepting 
properties of sazetidine-A and compare the results to those previously measured for 
cytisine. We now find, however, that the opposite hydrogen bonding pattern is not seen 
for sazetidine-A and that the pattern roughly follows the one observed for cytisine: a 
larger affect for the hydrogen-bonding acceptor in the A2B3 stoichiometry and a larger 
affect for the hydrogen-bonding donor in the A3B2 stoichiometry (Table 2.1, 
&)!
Figure 2.2). This pattern suggests an alternative explanation is needed to identify the 
properties of stoichiometry selective agonists.  
 
Table 2.1 Agonist Binding Model Comparison 
Stoichiometry Compound Wild Type EC50 (µM) a 
Relative 
Efficacy (%) b 
TrpB 
Cation-'  c 
H-Bond 
Donor d 
H-Bond 
Acceptor e 
 
Acetylcholine f 4.0 [100] 69 1.1 6.8 
Cytisine f 0.066 0 31 8.8 62 
Sazetidine-A 0.0046 80 22 5.7 10 
 
Acetylcholine f 87 [100] 540 1.1 8.5 
Cytisine f 15 7 30 27 14 
Sazetidine-A 0.14 0 58 11 5.0 
a See methods for wild type EC50 corrections. b Ratio of Imax of compound divided by Imax of acetylcholine. 
c Ratio of EC50 values for 4,5,6,7-tetraflouro-Trp and Trp incorporation at !4 W154 (Fig. 2A). d Ratio of 
EC50 values for Thr-!-hydroxy and Thr incorporation at !4 T155 (Fig. 2A).  e Ratio of EC50 values for 
Leu !-hydroxy and Leu incorporation at "2 L119 (Fig. 2A). f Previously reported values from 
Tavares et al. (12). Measured EC50 values reported in Table 2.2. 
 
2.3.2 Sazetidine-A and the "2 Complementary Face 
It has been shown that the unique hydrophobic appendage off of the pyridine ring 
of sazetidine-A gives the compound its subunit and receptor selectivity, and that the 
alcohol group at the end of the appendage does not play a significant role (15,18,19). 
Because this aliphatic adjunct interacts mostly with the complementary side, we began by 
focusing on the known differences between "4 and #2 subunits in this region (16). 
Previous investigations identified an "4-"4 binding site and suggested the differences 
between the “high” affinity ("4-#2) and “low” affinity ("4-"4) binding pockets are due 
to three key residues that reside on the complementary face (20-22). The #2(–) face 
residues (V109, F117, and L119) generate a hydrophobic pocket for the high affinity 
case, while the aligning "4(–) face residues (H114, Q122, and T124) create a 
hydrophilic, low affinity pocket (Figure 2.1, Figure 2.2). We have evaluated the triple 
mutant of the "4(–) face by swapping these three residues (H114V, Q122F, and T124L)  
&*!
A 
 
 
 
B 
 
 
 
Figure 2.2 Binding models of sazetidine-A and analogs. (A) Binding model for 
sazetidine-A based on established interactions seen with nicotine (12). The cation-' 
interaction is in purple, the hydrogen bond donor is in red, and the hydrogen bond 
acceptor is in green. (B) Crystal structure showing a sazetidine-A analog bound to 
Ct-AChBP (PDB: 4B5D) (15). The three key residues identified for the hydrophobic 
pocket associated with the #2 subunit (V109, F117, & L119) are shown, as is the TrpB 
residue from the "4 subunit. These residues were mutated into the crystal structure to 
show general spatial locations (no residue minimizations calculated). 
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to make them resemble the #2(–) face. We were able to generate receptor responses and 
measure an EC50 curve for sazetidine-A in the A3B2 receptor, which was not possible 
with the wild type "4 subunit (Table 2.3, Figure 2.3). The EC50 value for the triple 
mutant was about five-fold larger than the wild type A2B3 response, a small difference 
compared to having zero response in the wild type A3B2 receptor. Single mutations at 
the "4 subunit did not give rise to sazetidine-A response at low µM doses (Table 2.4). 
Combinations of double mutations saw some response towards low µM doses of 
sazetidine-A (Table 2.4). Mutations to make the # subunit more like the " subunit 
resulted in a large loss of function for sazetidine-A (Table 2.5). 
 
Table 2.3 Sazetidine-A EC50 (nM) Values 
Receptor EC50 (nM) Hill n Imax (µA) 
("4)2(#2)3 1.9 ± 0.1 2.0 ± 0.2 14 0.059 – 0.26 
("4)3(#2)2 NR – – – 
("4)2(#2)3 + 10 µM NS9283 2.0 ± 0.2 1.7 ± 0.2 13 0.067 – 1.6 
("4)3(#2)2 + 10 µM NS9283 1.1 ± 0.1 2.0 ± 0.2 14 0.4 – 7.2 
("4 H114V, Q122F, T124L)2(#2)3 4.8 ± 0.3 1.8 ± 0.2 13 0.18 – 1.3 
("4 H114V, Q122F, T124L)3(#2)2 9 ± 1 2.3 ± 0.6 14 0.71 – 6.2 
Agonist = Sazetidine-A 
NR = No Response 
 
2.3.3 Cytisine and the "2 Complementary Face 
Since these three residues had a large affect on receptor agonist selectivity and 
activation for sazetidine-A, we considered cytisine in an attempt to explain its selectivity 
for A3B2 over A2B3 receptors. Early chimera analysis showed that cytisine selectivity 
for human #4 over #2 subunits is strongly influenced by the extracellular region (23), and 
more recent analyses provide further details (24). Sequence alignment shows that of the 
three residues considered here, the only difference lies in the 117 position – #2 F117 and 
&-!
#4 L117 for the human subunits. For the rodent subunits considered here, #4 is Q117, 
which is identical to the "4 residue at this same position (Figure 2.1). In the rodent wild 
type "4#2 receptors, cytisine is a partial agonist with a biphasic response for the A3B2 
receptor.  No response is observed for the A2B3 receptor (Table 2.6), although signal can 
be obtained in receptors with hypersensitive mutations (see 2.5 Methods).  However, 
with the single mutation of F117Q in the #2 subunit, cytisine generated a sizable 
response for the A2B3 receptor. The mutation also raised the efficacy of the A3B2 
receptor compared to the wild type response (Table 2.6). 
 
 
Figure 2.3 Sazetidine-A EC50 curves. ("4)3(#2)2 cannot be activated by sazetidine-A. 
Responses can be obtained by mutating the complementary side of the "4 subunit to 
resemble the #2 subunit as seen with ("4 H114V, Q122F, T124L)3(#2)2 receptor. Also 
shown is wild type ("4)3(#2)2 receptor exposed to a combination of sazetidine-A and 
NS9283. 
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2.3.4 NS9283 and the !4 Complementary Face 
We next considered NS9283, which has a binding preference for the "4-"4 
interface (25). This compound has been previously characterized as a 
benzodiazepine-like positive allosteric modulator (PAM) for only the A3B2 
stoichiometry of receptors containing either "2 or "4 subunits (25,26). In addition, its 
effects are lost when the "4(–) face is mutated to resemble the #2(–) face in the region of 
the classical agonist binding site (27). Since we have molecules that selectively associate 
with "4-"4 (NS9283) and "4-#2 (sazetidine-A) interfaces, co-application should 
generate an A3B2 receptor response. As shown in Figures 2.3, 2.4 and Table 2.3, we 
find that individual applications of NS9283 and sazetidine-A show essentially no 
activation of wild type A3B2 receptors. However, co-application generates full activation 
of the receptor, compared to acetylcholine. The A3B2 "4 triple mutant (H114V, Q122F, 
T124L) was then exposed to similar conditions. The sazetidine-A response for the mutant 
was preserved, but the effect of NS9283 was completely lost (Table 2.3, Figure 2.4). 
The mutations eliminate the ability of NS9283 to bind at the "4-"4 interface and allow 
sazetidine-A to replace it in binding. These data suggest that occupation of an agonist at 
each " subunit is necessary for a receptor response. We generated the A3B2 #2 triple 
mutant (V109H, F117Q, L119T) to test if NS9283 could alone activate the channel. A 
response was seen in a dose dependent manner, suggesting the drug is a partial agonist, 
albeit, not potent or highly efficacious (Figure 2.4). Because NS9283 is sparingly 
soluble, a full EC50 curve could not be obtained. Nevertheless, we were able to transform 
a compound once designated as a PAM into an agonist, suggesting it could be binding to 
the canonical aromatic binding site. Also, due to its low potency and lower receptor 
'&!
expression, the corresponding A2B3 #2 triple mutant (V109H, F117Q, L119T) was 
inconclusive with regard to activation via NS9283.  
A 
 
B 
 
C 
 
Figure 2.4 Sample traces of responses to acetylcholine (ACh), sazetidine-A (Saz-A), and 
NS9283 (NS) to A3B2 receptors. Solid gray bars indicate drug application and dashed 
bars indicate a pause where drug remains present but the buffer wash has not started. 
Gaps between traces indicate buffer washes (see methods for duration of drug application 
and buffer washes). (A) Activation of wild type receptor by ACh at its EC50 value, and 
Saz-A and NS at the concentrations shown. (B) Activation of ("4 H144V, Q122F, 
T124L)3(#2)2. (C) Application of Imax concentrations of acetylcholine and two 
concentrations of NS to ("4)3(#2 V109H, F117Q, L119T)2. The * indicates a 1% by 
volume DMSO drug solution 
''!
2.4 Conclusions 
 The present work confirms and expands upon recent studies on the (–), 
complementary face of the agonist binding site of nAChRs. In particular, the long-held 
belief that agonist binding sites are formed only at "(+)/#(–) interfaces has been 
challenged by increasing evidence for a viable agonist binding site at "(+)/"(–) 
interfaces. Here we use several drugs that show some subtype specificity to probe this 
issue. The novel agonist sazetidine-A can only activate "4#2 receptors with an A2B3 
stoichiometry. In the alternative A3B2 stoichiometry, an "(+)/"(–) interface exists. The 
(–) face of such an interface is relatively polar, and evidently it is incompatible with the 
hydrophobic side chain of sazetidine-A that is expected to project into this region (recall 
that the OH group of sazetidine-A is not necessary for function). By mutating three 
residues in this region to be more hydrophobic and thus more like a #2(–) face, we can 
prepare A3B2 receptors that are quite responsive to sazetidine-A (Table 2.3). 
In a complementary series of experiments, we considered the drug NS9283, 
which binds only to "(+)/"(–) interfaces. It is unable to activate the receptor on its own, 
and it is thus an allosteric modulator. We reasoned that a combination of NS9283 and 
sazetidine-A would activate A3B2 receptors, with the former binding to the "(+)/"(–) 
interface and the latter to the "(+)/#(–) interfaces. Indeed, a mixture of NS9283 and 
sazetidine-A is quite potent at A3B2 receptors, while neither compound alone can 
activate the receptor. Taking this one step further, by mutating all interfaces so they 
resemble "(+)/"(–) interfaces, NS9283 becomes an agonist, rather than the allosteric 
modulator it is for the wild type receptor. 
'(!
We also applied this interface concept to cytisine, which has the reverse activation 
profile of sazetidine-A, in that it cannot activate the A2B3 receptor. By mutating one 
residue of the #2 subunit to that of the "4 subunit, we find that cytisine can activate the 
A2B3 receptor. In addition, this same mutation increased efficacy of cytisine for the 
A3B2 receptor from 7% to 16% (Table 2.6). 
In sum, this work shows the relevance of the "(+)/"(–) interface of nAChRs to 
achieving full receptor activation. This knowledge could be of great value to efforts to 
develop selective agonists for specific nAChR subtypes. 
 
Table 2.6 Cytisine-A EC50 (µM) Values 
Receptor EC50 (µM) [1] 
Hill 
[1] 
EC50 
(µM) [2] 
Hill 
[2] 
% 
[1] n 
Cyt 
Imax (µA) 
ACh 
Imax (µA) 
Efficacy 
("4)2(#2)3 NR – – – – – – 0.15 - 2.4 – 
("4)3(#2)2 
0.047 ± 
0.005 
1.8 ± 
0.3 6.0 ± 0.3 
1.3 ± 
0.1 22 16 
0.052 - 
2.9 0.94 - 33 7 ± 0.1 % 
("4)2(#2 
F117Q)3 
0.019 ± 
0.001 
1.6 ± 
0.1 – – – 11 
0.026 - 
0.10 
0.084 - 
2.5 22 ± 0.1 % 
("4)3(#2 
F117Q)2 
0.03 ± 
0.01 
1.0 ± 
0.3 3.3 ± 0.7 
1.1 ± 
0.2 33 17 
0.055 - 
4.0 0.51 - 20 16 ± 0.3 % 
Agonist = Cytisine 
NR = No Response 
 
2.5 Methods 
2.5.1 Molecular Biology  
Rat nAChR "4 and #2 subunits were in pAMV (unnatural mutagenesis) and 
pGEMhe (natural mutagenesis) vectors. Site-directed mutagenesis was performed using 
the QuikChange protocol (Stratagene). Circular DNA of "4 and #2 in pAMV was 
linearized with the NotI restriction enzyme and the plasmids in pGEMhe were linearized 
with the SbfI restriction enzyme. After purification (Qiagen), the T7 mMessage Machine 
kit (Ambion) was used to in vitro transcribe mRNA from linearized DNA templates. 
')!
QIAGEN’s RNeasy RNA purification kit was used to isolate the transcribed mRNA 
product. 
For unnatural amino acid incorporation, the amber (UAG) stop codon was used 
for all "4 subunit incorporation and the opal (UGA) stop codon was used for the #2 
subunit incorporation. 74-nucleotide THG73 tRNA (for UAG) and 74-nucleotide 
TQOpS’ tRNA (for UGA) were in vitro transcribed using the MEGAshortscript T7 
(Ambion) kit and isolated using Chroma Spin DEPC-H2O columns (Clontech). 
Synthesized unnatural amino acids coupled to the dinucleotide dCA were enzymatically 
ligated to the appropriate 74-nucleotide tRNA as previously described (13,28). 
 
2.5.2 Oocyte Preparation and Injection  
Xenopus laevis stage V and VI oocytes were harvested via standard protocols 
(28). For unnatural amino acid incorporation to the " subunit, the "4 and #2 mRNAs 
were mixed in a 3:1 ratio by mass to obtain the A2B3 receptor, and in a 100:1 ratio to 
obtain the A3B2 receptor. Unnatural amino acid incorporation to the # subunit used "4 
and #2 mRNA ratios of 1:20 and 10:1 to obtain the A2B3 and A3B2 receptors, 
respectively. mRNA mixtures and deprotected (photolysis) tRNA were mixed in a 1:1 
volume ratio, and 50 nL were injected into each oocyte. After injection, the oocytes were 
incubated at 18° C in ND96+ medium for 24 h. For the unnatural amino acids with 
reduced cation-' binding ability, a second round of injections following the same 
procedure was performed followed by incubation for an additional 24 h. The reliability of 
the unnatural amino acid incorporation was confirmed through 
read-through/reaminoacylation tests as previously performed (12). 
'*!
For the natural mutagenesis experiments, the "4 and #2 mRNAs were mixed in 
1:2 or 10:1 ratios by mass to obtain the A2B3 and A3B2 receptors, respectively (29). A 
total of 50 nL were injected to each oocyte, delivering an mRNA mass total of 25 ng. 
Oocytes were incubated at 18° C in ND96+ medium for 24-72 h. 
 
2.5.3 Chemical Preparation 
Acetylcholine chloride was purchased from Sigma-Aldrich and dissolved to 1 M 
stock solutions in ND96 Ca2+ free buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM 
HEPES at pH 7.5). Sazetidine-A dihydrochloride and (-)-cytisine were purchased from 
Tocris Bioscience and dissolved to 10 mM stock solutions in ND96 Ca2+ free buffer.  
NS9283 was synthesized following a patented protocol (30). 3-pyridylamidoxime 
and 3-cyanobenzoyl chloride were purchase from Sigma-Aldrich. 0.5 g of 
3-pyridylamidoxime was dissolved in 5.4 mL of pyridine. Then 0.6 g of 3-cyanobenzoyl 
chloride was added while stirring. The mixture was heated at reflux for 90 min and then 
cooled to room temperature. 200 mL of water was added and the white powder was 
filtered with two subsequent washes with water. The resulting powder was lyophilized 
overnight to remove the excess water. The reaction resulted in 60% yield, and the product 
was pure by LC-MS and NMR. 1H NMR (300 MHz, DMSO-d6) ! 9.26 (dd, J = 2.2, 0.9 
Hz, 1H), 8.82 (dd, J = 4.8, 1.6 Hz, 1H), 8.64 (td, J = 1.7, 0.7 Hz, 1H), 8.50 (ddd, J = 8.0, 
1.9, 1.1 Hz, 1H), 8.47 (dt, J = 6.0, 2.1 Hz, 1H), 8.22 (dt, J = 7.9, 1.4 Hz, 1H), 7.88 (td, J = 
7.9, 0.7 Hz, 1H), 7.65 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H); MS (+ES-API) m/z 249 (M+H)+. 
The purified compound, NS9283, was then dissolved to a 10 mM stock solution 
in DMSO. All drug solutions containing NS9283 were 0.1% DMSO (v/v) with the 
'+!
exception of the 100 mM dose, which had 1% DMSO (v/v). Appropriate controls of 1% 
DMSO (v/v) in ND96 Ca2+ free buffer only were applied to expressing cells to show no 
receptor response to the higher DMSO concentration. 
 
2.5.4 Electrophysiology 
The OpusXpress 6000A (Axon Instruments) in two-electrode voltage clamp mode 
was used for all electrophysiological recordings. The holding potential was set to -60 mV 
and the running buffer used was ND96 Ca2+ free solution for all experiments. All 
acetylcholine drug applications used 1 mL of drug solution applied over 15 s followed by 
a 2.5 min buffer wash at a rate of 3 mL min-1. All sazetidine-A, cytisine, NS9283, and 
co-applications used 1 mL of drug solution applied over 8 s with a 30 s pause before a 5 
min buffer wash at a rate of 3 mL min-1.  Dose-response measurements utilized a series of 
approximately three-fold concentration steps, spanning several orders of magnitude, for a 
total of eight to eighteen doses. Data were sampled at 50 Hz and then low-pass filtered at 
5 Hz. Experiments testing activity of compounds involved two to three acetylcholine 
doses of either EC50 or Imax values, followed by the test doses of compounds being 
probed, followed by one to two doses of the previous acetylcholine concentrations. 
Averaged and normalized data were fit to one or two Hill terms to generate EC50 
and Hill coefficient (nH) values. All currents for the activity testing were normalized to 
the highest acetylcholine dose applied pre-compound testing. The efficacy of compounds 
was measured as the ratio of the Imax of the compound divided by the Imax of 
acetylcholine. All acetylcholine EC50 values for the conventional mutations made in 
',!
pGEMhe are reported in (Table 2.7). Error bars represent standard error of the mean 
(SEM) values. 
 
Table 2.7 
Receptor EC50 (µM) [1] Hill [1] 
EC50 
(µM) [2] Hill [2] % [1] n Imax (µA) 
("4)2(#2)3 0.78 ± 0.02 1.1 ± 0.02 – – – 16 0.15 – 2.4 
("4)3(#2)2 7.2 ± 23 0.7 ± 0.4 106 ± 13 1.7 ± 0.5 26 15 1.7 – 31 
("4)2(#2)3 + 10 µM 
NS9283 0.48 ± 0.02 1.1 ± 0.05 – – – 12 0.095 – 7.2 
("4)3(#2)2 + 10 µM 
NS9283 0.15 ± 0.004 1.07 ± 0.03 – – – 14 0.42 – 42 
("4)2(#2 F117Q)3 1.6 ± 0.1 1.6 ± 0.1 – – – 15 0.033 – 0.28 
("4)3(#2 F117Q)2 9 ± 15 0.9 ± 0.4 134 ± 22 1.6 ± 0.3 25 14 1.5 – 15 
("4)2(#2 V109H, 
F117Q, L119T)3 
35 ± 1 1.5 ± 0.04 – – – 14 2.0 – 28 
("4)3(#2 V109H, 
F117Q, L119T)2 
180 ± 10 1.6 ± 0.1 – – – 12 0.16 – 6.3 
("4 H114V, Q122F, 
T124L)2(#2)3 
1.0 ± 0.03 1.1 ± 0.03 – – – 22 0.11 – 4.2 
("4 H114V, Q122F, 
T124L)3(#2)2 
2.7 ± 0.2 0.81 ± 0.03 – – – 16 0.89 – 18 
Agonist = Acetylcholine 
 
2.5.5 The Hypersensitive Mutation (L9’A) 
In the case of unnatural amino acid incorporation and mutagenesis scanning, EC50 
values were obtained using a hypersensitive mutation in the "4 subunit (L9'A). This 
mutation serves two purposes in the experimental setup: (1) the gain of function mutation 
gives a larger concentration window to probe effects of introduced mutations and (2) the 
pore mutation causes differences in rectification between the two stoichiometries, which 
can be probed via voltage jump experiments to confirm which stoichiometry is being 
observed (13,31). Since the EC50 is shifted from true wild type, a correction factor was 
applied according to the procedure of Moroni et al. to obtain the wild type EC50 value 
(32).  
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Chapter 3 
 
 
Probing the Non-Canonical Interface for Agonist Interaction  
with an !5 Containing Nicotinic Acetylcholine Receptor* 
 
 
*This chapter is adapted from: Christopher B. Marotta, Crystal N. Dilworth, Henry A. 
Lester, and Dennis A. Dougherty. Probing the Non-Canonical Interface for Agonist 
Interaction with an "5 Containing Nicotinic Acetylcholine Receptor. 
Neuropharmacology, 2014, 77, pages 342-349. Copyright 2013 Elsevier Ltd. The work 
described in this chapter was done in collaboration with Dr. Crystal N. Dilworth. 
%
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3.1 Abstract 
 Nicotinic acetylcholine receptors (nAChRs) containing the "5 subunit are of 
interest because genome-wide association studies and candidate gene studies have 
identified polymorphisms in the "5 gene that are linked to an increased risk for nicotine 
dependence, lung cancer, and/or alcohol addiction. To probe the functional impact of an 
"5 subunit on nAChRs, a method to prepare a homogeneous population of "5-containing 
receptors must be developed. Here we use a gain of function (9’) mutation to isolate 
populations of "5-containing nAChRs for characterization by electrophysiology. We find 
that the "5 subunit modulates nAChR rectification when co-assembled with "4 and #2 
subunits. We also probe the "5–"4 interface for possible ligand binding interactions. We 
find that mutations expected to ablate an agonist binding site involving the "5 subunit 
have no impact on receptor function. The most straightforward interpretation of this 
observation is that agonists do not bind at the "5–"4 interface, in contrast to what has 
recently been demonstrated for the "4–"4 interface in related receptors. In addition, our 
((!
mutational results suggest that the "5 subunit does not replace the "4 or #2 subunits and 
is relegated to occupying only the auxiliary position of the pentameric receptor. 
 
3.2 Introduction 
 
Nicotinic acetylcholine receptors (nAChRs) are widespread in the peripheral and 
central nervous systems. Because these receptors can be activated by nicotine as well as 
their native ligand acetylcholine, they have been associated with several health-related 
phenomena. Nicotine is the major addictive component of tobacco, and chronic tobacco 
use (smoking) has been implicated in many types of cancer as well as heart disease. Other 
related phenomena include an inverse correlation between smoking and Parkinson’s 
disease and the observation that patients with autosomal dominant nocturnal frontal lobe 
epilepsy who smoke have fewer seizures (1).   
nAChRs belong to the Cys-loop family of ionotropic receptors, which share a 
pentameric architecture arranged around a central ion-permeable pore. Many diverse 
subunit combinations can form functional receptors, and these combinations have distinct 
pharmacologies concerning responses to acute applications and chronic or repeated 
applications of nicotinic drugs. Neuronal nAChRs are composed of "2-"11 and #2-#4 
subunits and assemble as " plus # or "-only pentamers. The neuronal "4#2 receptor 
subtype is one of the two most abundant nAChRs in the central nervous system (CNS).  
Two "4#2 pentameric stoichiometries are known: ("4#2)2(#2) and ("4#2)2("4), which 
shall be referred to as A2B3 and A3B2, respectively (2).  Subunit stoichiometry of 
nAChRs is important in determining pharmacology, stability, and subcellular location. 
()!
The A2B3 stoichiometry displays higher sensitivity to nicotine and has been proposed to 
play an especially prominent role in nicotine addiction.  
Several brain regions express receptors that contain an "5 subunit 
("5* receptors), including the substantia nigra pars compacta, subthalamic nucleus, 
medial habenula, prefrontal cortex, and hippocampus. Receptors containing "5 play a 
part in nicotine self-administration and nicotine withdrawal (3). These receptors are also 
important for dopamine release and attention tasks (4-6). The "4#2"5 receptors are more 
permeable to Ca2+ than "4#2 receptors and have a higher sensitivity to nicotine (7). The 
"5 subunit has been assumed to occupy the fifth “auxiliary” position in pentameric 
receptors, and it has not previously been thought to participate in forming a functional 
agonist binding site. However, recent studies have proposed that a low affinity binding 
site exists in the A3B2 "4#2 receptor at the "4–"4 interface (Fig. 3.1) (8-10), in addition 
to the higher affinity binding sites at the "4–#2 interface. This new binding location 
utilizes an auxiliary subunit interface, leading to questions as to whether "5 can 
participate in a similar motif.  
Given the precise localization and unique functional properties of "5* receptors, 
"5 presents itself as a valuable therapeutic target. However, currently there are no 
pharmacological ligands that can functionally isolate "5* receptors. If "5 does 
participate in a ligand-binding site at the "5–"4 interface, this interaction would be a 
vital target for selective ligand development. 
 ! !
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Fig. 3.1 (A) View of nAChRs from the extracellular solution. The "4#2 receptor has two 
"4 subunits, two #2 subunits, and two conventional antagonist/agonist binding sites, at 
"4–#2 interfaces. The fifth subunit is the “accessory” subunit, and in this study three 
possibilities are the "4, "5 or #2 subunits. The accessory subunit may also contribute to 
a binding interface, shown by “?” (B) Sequence alignment of the mouse nAChR subunits 
highlighting the aromatic box residue locations on loops D, A, B, and C (in sequence). 
The residues shown are identical to their human sequence except the final residue (Cys) 
in the mouse "5 subunit is a tyrosine (Tyr, Y) in the human subunit. Note that TrpD is on 
the “complementary” face of a subunit, and so it is not expected to contribute to an 
"5-"4 interface.  
 
3.3 Materials and Methods 
3.3.1 Molecular Biology  
Mouse nAChR "5 wt, "5-GFP, "4, and #2 subunits were in pGEMhe. The 
QuikChange protocol (Stratagene) was used for site-directed mutagenesis. Circular DNA 
for "5, "4, and #2 was linearized as follows: SphI restriction enzyme for "5 plasmids 
and SbfI restriction enzyme for the "4 and #2 plasmids. After purification (Qiagen), 
mRNA was synthesized from linearized DNA template through run-off transcription by 
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using the T7 mMessage Machine kit (Ambion). Purification of mRNA was performed 
using QIAGEN’s RNeasy RNA purification kit. 
 
3.3.2 Electrophysiology Studies 
3.3.2.1 Xenopus Oocyte Preparation and Injection  
Xenopus laevis stage V and VI oocytes were harvested via standard protocols 
(11). The "5 mRNA was mixed with "4 and #2 mRNA in a 10:1:1 ratio by mass and 50 
nl were injected into the oocytes delivering 40 ng of total mRNA. After injection, oocytes 
were incubated at 18° C in ND96+ medium for 24-96 h. The control experiments of only 
"4 and #2 mRNA with ratios of 1:1, 1:2, and 10:1 had total mRNA amounts of 6.67 ng, 
20 ng and 21 ng, respectively.  
 
3.3.2.2 Chemical Preparation 
Acetylcholine chloride, (–)-nicotine tartrate, and mecamylamine hydrochloride 
were purchased from Sigma-Aldrich and dissolved to 1 M and 0.25 M stock solutions in 
ND96 Ca2+ free buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES at 
pH 7.5), respectively.  
 
3.3.2.3 Electrophysiological Experimental Protocols  
Electrophysiological recordings were performed using the two electrode voltage 
clamp mode with the OpusXpress 6000A (Axon Instruments). The holding potential was 
-60 mV. All recordings involving "5* receptors and "4#2 receptors used the 
ND96 Ca2+ free solution as the running buffer.  All measurements used 1 mL of drug 
(,!
solution applied during 15 s (except 25 s for current-voltage experiments) followed by a 
2 min buffer wash except for nicotine application which received a 5 min buffer wash. 
Dose-response measurements utilized a series of approximately three-fold concentration 
steps, spanning several orders of magnitude, for a total of eight to eighteen doses. Data 
were low-passed filtered at 5 Hz and digitized at 125 Hz.  
Mecamylamine experiments involved three acetylcholine doses, followed by two 
co-application doses of acetylcholine and mecamylamine, followed by two doses of 
acetylcholine only. Before each co-application, there was a 30 s pre-incubation of 
mecamylamine only.  
 
3.3.3 Data Analysis 
3.3.3.1 Dose-Response Analysis  
Averaged and normalized data were fit to one or two Hill terms to generate EC50 
and Hill coefficient (nH) values. All currents for the mecamylamine experiment were 
normalized to the highest current response pre-mecamylamine addition. The percentage 
recovery was calculated by comparing pre- and post-mecamylamine applications. 
 
3.3.3.2 Current-Voltage Analysis 
I-V relations were generated from 400 ms test pulses, applied at intervals of 
500 ms, ranging from -110 mV to +70 mV in 20 mV increments. To minimize distortions 
from desensitization or ion accumulation, the increments proceeded in both depolarizing 
and hyperpolarizing directions during each drug application, and averaged data were 
analyzed. To isolate agonist-induced currents, we subtracted records taken in buffer only. 
(-!
The current was averaged during 200 to 400 ms after the jump, and then normalized to 
the value at -110 mV. 
 
3.3.3.3 Error Analysis 
Error bars on dose-response curves represent standard error of the mean (SEM) 
values. Maximal current values (wild type vs. V9’S "5 subunit) and voltage jump 
comparisons (at +70 mV) were subjected to Student t Test analysis and gave 
t probabilities < 0.001.  
 
3.4 Results 
3.4.1 Expression of an !5-Containing Receptor 
Accurate interpretation of structure-function relationships from 
electrophysiological responses requires expression of a homogeneous receptor 
population. As such, a method to prepare and confirm a homogenous population of 
"5* receptors must first be established before we can begin to interpret results from 
mutational analysis of the putative "5–"4 interface. "5 presents a unique challenge 
because of its role as an accessory subunit. When "5 is co-expressed with "4 and #2 
subunits, we consider the possibility of three different receptor populations on the cell 
surface: ("4#2)2(#2), ("4#2)2("4), and ("4#2)2("5). The assumption that "4#2"5 
receptors have an ("4#2)2("5) stoichiometry is partly based on analogy to the muscle-
type receptor, which contains two conventional binding interfaces ("/$(&) and "/%) and 
then a single auxiliary subunit, #. Previously, differences in EC50 values and rectification 
).!
behaviors allowed a distinction to be made between the two "4#2 receptor 
stoichiometries (12). Here, we apply similar strategies to evaluate "5* receptors. 
Varying mRNA injection ratios in oocytes can bias assembly to a specific 
receptor stoichiometry (2,12,13). Specifically, using excess of "5 mRNA compared to "4 
and #2 mRNA promotes preferential assembly with an "5 subunit (14). A ratio of 10:1:1 
of "5:"4:#2 mRNA was used to bias the system toward incorporation of the "5 subunit. 
As seen in (Fig. 3.2), injection of a 1:1 ratio of "4:#2 mRNA produces a biphasic dose-
response relation, reflecting the presence of A2B3 (high affinity) and A3B2 (low affinity) 
forms of the "4#2 receptor.  However, a monophasic dose-response relation is clearly 
seen upon the addition of the "5 mRNA (14). mRNA injections of 1:2 of "4:#2 
(resulting in A2B3 receptors) and 10:1 of "4:#2 (resulting in A3B2 receptors) were 
performed in order to compare EC50 values of the two "4#2 receptor stoichiometries with 
the new value obtained from introducing the "5 mRNA (Fig. 3.2, Table 3.1). We find 
that the EC50 value resulting from 10:1:1 "5:"4:#2 mRNA injection is nearly identical to 
that for the A2B3 receptor. This could indicate that "5-containing receptors 
coincidentally have nearly the same EC50 as A2B3 "4#2 receptors, or that the addition of 
the "5 mRNA is attenuating the expression of the A3B2 receptor, resulting in a single 
population of A2B3 receptors at the surface. An additional challenge to evaluating these 
putative "4#2"5 receptors was the low agonist-induced current (tens to hundreds of nA) 
seen in these experiments. 
To address the first issue, we tested the response to voltage-jump protocols that 
we had previously used to distinguish A2B3 and A3B2 "4#2 receptors (12). Figure 3.3 
)%!
shows that there is a distinct loss of rectification for receptors prepared by a 10:1:1 
"5:"4:#2 mRNA injection compared to A2B3 and A3B2 receptors. This result suggests 
that we have "5* receptors on the surface of the oocyte. 
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Fig. 3.2 (A) Dose response relations for the mouse "4#2 receptor with a 1:1 injection 
ratio, and for the mouse ("4#2)2("5) receptor with a 10:1:1 "5:"4:#2 mRNA injection 
ratio. (B) Comparison of dose-response relations for the two stoichiometries of the mouse 
"4#2 receptors (A2B3 and A3B2) and the mouse ("4#2)2("5) receptor with and without 
the "5V9’S mutation. 
 
To overcome the small currents that were hampering our efforts to fully 
characterize these channels, we introduced an often-used reporter mutation at the 9’ 
position of the pore lining M2 helix (15-18).  Mutations in this region frequently result in 
increased expression levels. In addition, 9’ mutations typically cause a gain of function in 
the receptor, evidenced by a reduction in EC50 values and due to an altered Popen, without 
affecting the ligand-binding domain (19). Most subunits of nAChRs have a conserved 
Leu at the 9’ position, but the accessory subunits "5 and #3 contain a Val in that position. 
The V9’T (20) or V9’S (21) mutation has been employed to study "3#4"5 nAChRs, but 
not "4#2"5 nAChRs. In the present work a V9’S mutation was introduced into the "5 
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subunit, and the above experiments were repeated with the "5V9’S subunit. Interestingly, 
we observe nearly identical EC50 values for ("4#2)2("5) and ("4#2)2("5V9’S) as shown 
in (Fig. 3.2). However, a substantial increase in agonist-induced current was observed 
(Table 3.1), and more consistent responses among batches of oocytes were noted. These 
observations further support the notion that the "5 subunit has been incorporated, since 
the only change between the experiments was the mutation in the "5 subunit. 
Table 3.1 
Receptor (Ratio) EC50 (µM) Hill n Current 
Range (µA) 
"4 wt #2 wt (1:1) 0.9 ± 0.2 (low) 0.9 ± 0.1 (low) 25 -0.14 to -7.0 
 110 ± 15 (high) 2.1 ± 0.5 (high) - - 
"4 wt #2 wt (1:2) 0.80 ± 0.05 1.15 ± 0.7 13 -0.15 to -0.97 
"4 wt #2 wt (10:1) 141 ± 27 2.0 ± 0.7 17 -1.5 to -16 
"4L9'A #2 wt (1:10) 0.39 ± 0.02 1.25 ± 0.7 13 -0.31 to -7.2 
"4L9'A #2 wt (10:1) 0.046 ± 0.001 1.27 ± 0.04 13 -4.1 to -22 
"5 wt "4 wt #2 wt (10:1:1) 0.55 ± 0.05 0.95 ± 0.1 12 -0.027 to -0.20 
"5V9'S "4 wt #2 wt (10:1:1) 0.57 ± 0.01 1.14 ± 0.01 26 -0.38 to -5.7 
"5V9'S GFP "4 wt #2 wt (10:1:1) 0.76 ± 0.02 1.07 ± 0.03 17 -0.34 to -7.2 
Agonist = Acetylcholine      
 
3.4.2 The !5V9’S Mutation Confers Distinct Physical Properties Allowing for Definitive 
Establishment of the Subunit’s Incorporation  
The two stoichiometries of the "4#2 receptor are distinguishable by their distinct 
EC50 values. However, their rectification properties are similar (Fig. 3.2, 3.3 and Table 
3.1, 3.2). Previous studies have shown that introduction of an L9’A mutation in the "4 
subunit changes the rectification behavior of "4#2 receptors (12). Xiu et al. report that 
the A2B3 receptor rectifies much more markedly than the A3B2 when the "4 L9’A 
mutation is present (12). Similarly, we find that introduction of the V9’S mutation to the 
"5 subunit produces a more marked loss of rectification compared to the wild type "5 
subunit (Fig. 3.3). In anticipation of future studies on receptor trafficking and 
)'!
localization, we prepared receptors with the V9’S mutation and meGFP inserted in the 
M3-M4 loop of the "5 subunit. This receptor also gives a wild type EC50 and a loss of 
rectification (Table 3.1, 3.2). 
A 
 
B 
 
Fig. 3.3 Summary of rectification analysis. (A) Sample traces of the voltage jump 
experiment. The superimposed command voltage sweeps (left) and the ACh-induced 
currents (right) for the ("4#2)2("5V9’S) receptor are shown. (B) Comparison of current-
voltage relations for the two stoichiometries of the mouse "4#2 receptors (A2B3 and 
A3B2) and the mouse ("4#2)2("5) receptor with and without the 9’ mutation. 
 
In addition to the EC50 and rectification data, we also sought to more fully 
characterize the ("4#2)2("5V9’S) receptor. Mecamylamine has been extensively 
characterized as an open channel blocker with a slow wash off time for the 
"4#2 receptor (22). A distinctive property of this open channel blocker is its “trapping”  
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Table 3.2 
Receptor (Ratio) 
ACh Induced 
Current at +70 mV 
(Normalized) 
Current Range (µA) 
at -110mV 
Current Range (µA) 
at +70mV n 
"4 wt #2 wt (1:1*) 0.01 ± 0.01 -0.35 to -1.8 -0.02 to 0.11 34 
"4 wt #2 wt (1:2) 0.01 ± 0.01 -0.10 to -1.4 -0.03 to 0.09 34 
"4 wt #2 wt (10:1) 0.067 ± 0.008 -1.7 to -24 0.08 to 2.0 60 
"4L9'A #2 wt (1:10) 0.054 ± 0.005 -0.23 to -5.0 -0.006 to 0.25 28 
"4L9'A #2 wt (10:1) 0.34 ± 0.01 -1.0 to -18 0.39 to 6.4 31 
"5 wt "4 wt #2 wt 
(10:1:1) 0.10 ± 0.03 -0.073 to -0.14 -0.013 to 0.027 6 
"5V9'S "4 wt #2 wt 
(10:1:1) 0.34 ± 0.02 -0.56 to -2.5 0.15 to 1.2 34 
"5V9'S GFP "4 wt #2 wt 
(10:1:1) 0.33 ± 0.02 -0.71 to -1.9 0.27 to 0.5 12 
ACh doses were the corresponding receptor's EC50 value for the voltage jump experiments  
*The smaller of the two EC50 values was used for this measurement   
 
behavior: it associates and disassociates preferentially from the open pore of the receptor 
(23). Because of the prolonged wash-off time, subsequent applications of an agonist are 
generally needed to dissociate the molecule from the pore.  
The results in Figure 3.4 show a dramatic difference between the 
("4#2)2("5V9’S) receptor and the "4#2 receptor. When the "5V9’S subunit is present, 
mecamylamine washes off the receptor completely within 120 s. We also find that 
introducing an L9’A mutation into the "4 subunit results in mecamylamine successfully 
washing out of both the A2B3 and A3B2 receptors (Table 3.3). This suggests that the 
observed results with the "5V9’S subunit are due to the 9’ mutation rather than an 
intrinsic property of the subunit. However, this still generates an important observation 
for this system. For studies of the ("4#2)2("5V9’S) receptor, the observation of nearly 
complete response recovery within 120 s indicates that we have prepared a receptor 
population on the plasma membrane that is highly enriched in "5* receptors, if not 
completely homogeneous. If a more mixed population containing both "5* and "4#2 
receptors was being expressed, the response would have recovered less fully. Results 
))!
from the rectification and open channel blocker experiments strongly indicate that we are 
able to express on the oocyte surface an "5* receptor population that is homogeneous or 
very nearly so. With this, we can now begin to investigate the "5–"4 interface, knowing 
that responses from introduced mutations are directly due to changes in the 
("4#2)2("5V9’S) receptor. 
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Fig. 3.4 (A) Response recovery following co-application of acetylcholine and 
mecamylamine following the protocol in part B. (B) A sample current trace of a single 
oocyte recording for each of the subunit combinations indicated. The "4#2 nAChR is in 
red and the ("4#2)2("5V9’S) nAChR is in black. A 120 s wash period occurred between 
each dose.  
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Table 3.3 
Receptor (Ratio) Signal Recovery Current Range (µA) n 
"5V9'S "4 wt #2 wt (10:1:1) 80 ± 2 % -0.46 to -1.0 14 
"4 wt #2 wt (1:2) 12 ± 1 % -0.16 to -1.5 13 
"4 wt #2 wt (10:1) 17 ± 2 % -1.3 to -22 16 
"4L9'A #2 wt (1:10) 56 ± 2 % -0.08 to -0.84 15 
"4L9'A #2 wt (10:1) 93 ± 5 % -1.3 to -20 14 
ACh doses were 10 times the corresponding receptor's EC50 value for the mecamylamine experiments. 
Mecamylamine was kept at constant 100 µM value to ensure full channel block 
 
3.4.3 Mutational Analysis of the Aromatic Box at the !5–!4 Interface Showed No 
Functional Impact  
The aromatic box of nAChR agonist binding sites is highly conserved and has 
been extensively characterized (24-28). The aromatic box mediates an essential cation-' 
interaction between the positively charged portion of the ligand and one (or occasionally 
two) of the five aromatic residues (A, B, C1, C2, and D) of the aromatic box. In fact, this 
aromatic box structure has been seen in a wide range of binding sites for cationic 
structures (29). The sequence alignment in Figure 3.1 highlights the residues of interest 
for studying the "5 subunit. Residues TrpB, TyrC2, and TyrA have previously been 
shown to be involved in cation-' interactions in other receptors, and these residues would 
be part of the principal component of an aromatic box contributed by "5 if an "5–"4 
binding site exists. The TrpD residue of the "5 subunit was also investigated to probe the 
possibility of agonist binding at the #2–"5 interface. In addition, this mutation can 
subsequently probe the possibility that "5 subunits were replacing #2 subunits that would 
normally participate in the "4–#2 binding site. Interestingly, the C1 residue of the 
aromatic box that is typically a Tyr in " subunits is an Asp in the "5 subunit. 
 An alanine scan of the aromatic residues of "5 was performed. As shown in 
Tables 3.4, 3.5, negligible changes in EC50 were seen in all cases for both ACh and 
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nicotine as agonists. Since the C1 site is not aromatic in the "5 subunit, an Asp-to-Tyr 
mutation was introduced. Again, no change in EC50 was seen. Current-voltage relations 
confirmed the inclusion of the "5 subunit for all the mutations (Table 3.6). 
Table 3.4 
 Acetylcholine    Fold  
Shift 
Current 
Range (µA) Receptor (Ratio) EC50 (µM) Hill n 
"4 wt #2 wt (1:2) 0.80 ± 0.05 1.2 ± 0.1 13 - 0.15 - 0.97 
"4 wt #2 wt (10:1) 140 ± 30 2.0 ± 0.7 17 - 1.5 - 16 
"5V9'S "4 wt #2 wt (10:1:1) 0.57 ± 0.01 1.1 ± 0.01 26 - 0.38 - 5.7 
"5V9'S W98A (Trp D) 1.1 ± 0.08 1.1 ± 0.07 10 1.9 0.038 - 1.5 
"5V9'S F136A (Tyr A) 0.66 ± 0.02 1.2 ± 0.04 10 1.2 0.21 - 0.54 
"5V9'S W191A (Trp B) 0.55 ± 0.03 1.2 ± 0.08 19 1 0.068 - 0.67 
"5V9'S D232Y (Tyr C1) 0.60 ± 0.02 1.3 ± 0.04 13 1 0.20 - 1.2 
"5V9'S Y237A (Tyr C2) 0.82 ± 0.03 1.2 ± 0.05 16 1.4 0.067 - 0.41 
 
Table 3.5 
 Nicotine   Fold  
Shift 
Current 
Range (µA) Receptor (Ratio) EC50 (µM) Hill n 
"4 wt #2 wt (1:2) 0.17 ± 0.01 1.4 ± 0.1 15 - 0.07 - 0.45 
"4 wt #2 wt (10:1) 6.7 ± 1 0.86 ± 0.1 12 - 0.39 - 3.3 
"5V9'S "4 wt #2 wt (10:1:1) 0.19 ± 0.02 1.4 ± 0.2 34 - 0.11 - 1.4 
"5V9'S W98A (Trp D) 0.27 ± 0.02 1.4 ± 0.1 15 1.4 0.030 - 0.65 
"5V9'S F136A (Tyr A) 0.16 ± 0.02 1.3 ± 0.2 12 0.8 0.095 - 0.30 
"5V9'S W191A (Trp B) 0.16 ± 0.01 1.4 ± 0.1 13 0.8 0.092 - 1.8 
"5V9'S D232Y (Tyr C1) 0.19 ± 0.02 1.4 ± 0.2 12 1 0.56 - 3.3 
"5V9'S Y237A (Tyr C2) 0.17 ± 0.01 1.3 ± 0.1 10 0.9 0.41 - 3.1 
 
Table 3.6 
Receptor (Ratio) ACh Induced Current at +70 mV (Normalized) 
Current Range (µA) 
at -110mV 
Current Range (µA)  
at +70mV n 
"5V9'S "4 wt #2 
wt (10:1:1) 0.34 ± 0.02 -0.56 to -2.5 0.15 to 1.2 34 
"5 V9'S W98A 
(Trp D) 0.35 ± 0.03 -0.13 to -1.4 0.056 to 0.39 16 
"5 V9'S F136A 
(Tyr A) 0.39 ± 0.03 -0.13 to -0.68 0.040 to 0.43 16 
"5 V9'S W191A 
(Trp B) 0.43 ± 0.03 -0.18 to -3.2 0.064 to 1.2 18 
"5 V9'S D232Y 
(Tyr C1) 0.37 ± 0.41 -0.34 to -6.1 0.10 to 1.7 14 
"5 V9'S Y237A 
(Tyr C2) 0.38 ± 0.03 -0.12 to -6.0 0.080 to 1.4 15 
ACh doses were the corresponding receptor's EC50 value for the voltage jump experiments 
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3.5 Discussion 
Accessory subunits play important roles in nAChR function, because they confer 
unique properties to their parent receptors. Not surprisingly, expression of these subunits 
is highly regulated and restricted to specific brain regions (5,30). Some examples of this 
region specificity are found in the cerebral cortex, where "5* receptors are expressed 
only in layer VI, and in the striatum, where "5 may be expressed only in the 
dopaminergic neurons of the caudatoputamen, but not in the nucleus accumbens region 
(31-33). "5 is of particular interest because well-replicated human genome-wide 
association studies have identified a single nucleotide polymorphism that affects the risk 
for nicotine dependence, lung cancer, and alcohol dependence (34-36). This mutation, 
encoding Asn at position 398 in the coding region of the CHRNA5 gene, also affects 
nicotine self-administration in mice (3,37). Thus, it would be beneficial to be able to 
probe functional differences of "5* receptors using pharmacological agents in vivo. 
Here we aimed to elucidate possible ligand binding motifs involving the "5 
subunit in the ("4#2)2("5) receptor. The " designation for "5 arose from the existence of 
adjacent Cys residues in the C loop (Fig. 3.1B), although other aspects of the C loop, 
such as replacement of conserved TyrC1 and residue deletions, are more #-like. Also, "5 
is unable to form functional receptors unless other " subunits are also expressed. As such, 
"5 is generally considered to be an accessory subunit. However, the discovery of an "4–
"4 binding interface in A3B2 "4#2 receptors suggests the possibility of an unusual 
binding site at the "5–"4 binding interface (8).  
To address this question, we first optimized our expression system to ensure a 
homogeneous, or at least very highly enriched, population of receptors. Early studies on 
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wild type receptors in oocytes suggested that biasing mRNA injection ratios strongly 
toward "5 would produce a homogeneous population of "5-containing receptors. 
However, expression levels were low, making thorough characterization challenging. 
Introducing a V9’S mutation into the "5 subunit resulted in increased agonist responses, 
allowing greater consistency and reproducibility between experiments.  
We have two lines of evidence to support the argument that "5 is incorporated 
into the receptor and that the population of receptors on the oocyte plasma membrane is 
homogeneous or very nearly so. First, we see altered rectification behavior for channels 
with "5 vs. pure "4#2 receptors (Fig. 3.3). The effect is evident in fully wild type 
receptors, but is more apparent for the "5V9’S receptors. This is the second system for 
which we have observed that a 9’ mutation can markedly affect channel rectification 
properties. A single 9’ mutation in the accessory subunit location – "5V9’S in this case – 
is sufficient to alter the rectification properties of the receptor. In the "4#2 receptor, the 
A3B2 receptor with the L9’A mutation in the "4 subunit shows a marked loss of 
rectification, but replacing the third "4L9’A subunit with a #2 subunit (A2B3) restores 
rectification (Table 3.2) (12). 
The second argument for incorporation of "5 into our expressed receptors is 
based on altered behavior by the channel blocker mecamylamine. For "4#2 receptors, 
mecamylamine blockade washes out very slowly, and most efficiently when agonist is 
also added (Fig. 3.4B). When the "5V9’S subunit is included, mecamylamine blockade 
washes out readily. Note that the washout is essentially complete, arguing that all, or very 
nearly all, receptors contain the "5 subunit. Any population of "4#2 receptors would 
have led to residual mecamylamine block. The alteration of mecamylamine block is only 
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seen when the V9’S mutation is present in "5. An "4L9’A mutation also impacts 
mecamylamine block, indicating that it is the pore mutation that is affecting block, not 
the intrinsic properties of the "5 subunit. Presumably, mecamylamine binds within the 
pore near the 9’ residue. 
Having established that "5 is incorporated into the receptors, we can comment on 
its impact on receptor function. It is interesting that the "4#2"5 receptor has essentially 
the same EC50 as the ("4#2)2(#2) receptor. This strongly suggests that the "5 subunit is 
not displacing an "4 subunit that contributes to an agonist binding site, as this should 
produce an EC50 change, especially since any mutation of TyrC1 in nAChR agonist 
binding sites shifts EC50 strongly, and "5 is mutated at that site. The same argument 
could be made that "5 does not replace a #2 subunit that contributes to the agonist 
binding site, although perhaps less forcefully since the two have similar sequences in 
loop D. Note that if two (or more) "5 subunits were incorporated, then one of the 
canonical "4/#2 interfaces would disappear, and again it is difficult to imagine that 
happening without EC50 being impacted. It is surprising that the V9’S mutation in "5 
does not shift EC50. Typically, introducing a polar substituent at any 9’ position of a 
nAChR leads to a drop in EC50. In other cases the wild type 9’ residue is Leu not Val, but 
it is not obvious why that would lead to a change in behavior  
To probe for the existence of an agonist binding site at the "5–"4 interface, we 
mutated the conserved residues in "5 that would contribute to the aromatic box of such a 
binding site (TyrA, TrpB, TyrC1, and TyrC2). Converting an aromatic to an Ala or 
converting the Asp that aligns with TyrC1 to Tyr did not have a marked effect on agonist 
responses. These are fairly dramatic mutations that would produce very substantial shifts 
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in EC50 in established agonist binding sites. We also mutated TrpD of "5 to Ala, to probe 
whether "5 replaces a #2 subunit and contributes a complementary face, interacting with 
an "4 subunit. Again, no meaningful impact on receptor function was seen. 
The most straightforward interpretation of these results is that there is no ACh or 
nicotine binding site at the "5–"4 interface, and so mutation of key residues has no 
functional impact. We cannot rule out the possibility that ACh binds to the "5–"4 
interface, but that the binding does not meaningfully impact receptor function. Also, our 
assay precludes the application of drugs at concentrations greater than 100 µM for "5* 
receptors, and so it is possible that there is a very low affinity binding site (dissociation 
constant on the order of mM).  However, the biological implications of such a site seem 
negligible. Also, it is possible that other drugs could bind at the "5–"4 interface, and that 
binding at the "5–"4 interface could have a functional consequence in receptors in which 
the conventional, "4–#2 interfaces have in some way been compromised.  
Although it does not contribute an ACh binding site in the nAChRs studied here, 
the "5 subunit can play other important roles. The "5 subunit also co-assembles with "3 
and #4 subunits to form functional nAChRs, especially in peripheral ganglia and in the 
medial habenula-interpeduncular nucleus pathway (3), and it has been shown to modulate 
expression levels of these receptors (38). Also, the "5 subunit could impart pore-related 
differences such as Ca2+ permeability (7), and intracellular loop-related differences such 
as endoplasmic reticulum exit and synaptic targeting (39). 
In conclusion, we have developed a protocol for preparing highly enriched 
populations of ("4#2)2("5) nAChRs, and we have shown that mutations that would be 
expected to disrupt an "5–"4 interfacial binding site do not affect receptor function. In 
*&!
addition, we have shown that "5 subunits only occupy the auxiliary position when co-
assembled with "4 and #2 subunits. Further studies will be required to develop a strategy 
for selectively probing "5* receptors with pharmacological agents. 
 
3.6 Acknowledgments 
We thank Bruce N. Cohen for help with data interpretation. This work was supported by 
grants from the NIH (NS034407, DA017279, DA280382), NIH/NRSA (GM07616), and 
the California Tobacco-Related Disease Research Program from the University of 
California (19XT-0102). 
  
*'!
3.7 References 
 
1. Brodtkorb, E., and Picard, F. (2006) Tobacco habits modulate autosomal 
dominant nocturnal frontal lobe epilepsy. Epilepsy and Behavior 9, 515-521 
2. Nelson, M., Kuryatov, A., Choi, C., Zhou, Y., and Lindstrom, J. (2003) Alternate 
Stoichiometries of the "4#2 Nicotinic Acetylcholine Receptors. Molecular 
Pharmacology 63, 332-342 
3. Fowler, C. D., Lu, Q., Johnson, P. M., Marks, M. J., and Kenny, P. J. (2011) 
Habenular "5 nicotinic receptor subunit signalling controls nicotine intake. 
Nature 471, 597-601 
4. Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. 
C., and Grady, S. R. (2004) Subunit Composition and Pharmacology of Two 
Classes of Striatal Presynaptic Nicotinic Acetylcholine Receptors Mediating 
Dopamine Release in Mice. Molecular Pharmacology 65, 1526-1536 
5. Gotti, C., Zoli, M., and Clementi, F. (2006) Brain nicotinic acetylcholine 
receptors: native subtypes and their relevance. Trends Pharmacol Sci 27, 482-491 
6. Bailey, C. D., De Biasi, M., Fletcher, P. J., and Lambe, E. K. (2010) The nicotinic 
acetylcholine receptor "5 subunit plays a key role in attention circuitry and 
accuracy. J Neurosci 30, 9241-9252 
7. Kuryatov, A., Onksen, J., and Lindstrom, J. (2008) Roles of accessory subunits in 
"4#2(*) nicotinic receptors. Molecular Pharmacology 74, 132-143 
8. Mazzaferro, S., Benallegue, N., Carbone, A., Gasparri, F., Vijayan, R., Biggin, P. 
C., Moroni, M., and Bermudez, I. (2011) Additional acetylcholine (ACh) binding 
site at "4/"4 interface of ("4#2)2"4 nicotinic receptor influences agonist 
sensitivity. J Biol Chem 286, 31043-31054 
9. Rohde, L. A., Ahring, P. K., Jensen, M. L., Nielsen, E. O., Peters, D., Helgstrand, 
C., Krintel, C., Harpsoe, K., Gajhede, M., Kastrup, J. S., and Balle, T. (2012) 
Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine 
"4#2 receptors: unique role of halogen bonding revealed. J Biol Chem 287, 4248-
4259 
10. Harpsoe, K., Ahring, P. K., Christensen, J. K., Jensen, M. L., Peters, D., and 
Balle, T. (2011) Unraveling the high- and low-sensitivity agonist responses of 
nicotinic acetylcholine receptors. J Neurosci 31, 10759-10766 
11. Nowak, M., Gallivan, J. P., Silverman, S., Labarca, C. G., Dougherty, D. A., and 
Lester, H. A. (1998) In Vivo Incorporation of Unnatural Amino Acids into Ion 
Channels in Xenopus Oocyte Expression System. Methods Enzymol 293, 504-530 
12. Xiu, X., Puskar, N. L., Shanata, J. A., Lester, H. A., and Dougherty, D. A. (2009) 
Nicotine binding to brain receptors requires a strong cation-pi interaction. Nature 
458, 534-537 
13. Moroni, M., Zwart, R., Sher, E., Cassels, B. K., and Bermudez, I. (2006) "4#2 
nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, 
stoichiometry, and sensitivity to long-term exposure to nicotine. Molecular 
Pharmacology 70, 755-768 
14. Ramirez-Latorre, J., Yu, C. R., Qu, X., Perin, F., Karlin, A., and Role, L. (1996) 
Functional contributions of "5 subunit to neurona acetycholine receptor channels. 
Nature 380, 347-352 
*(!
15. Filatov, G. N., and White, M. M. (1995) The Role Of Conserved Leucines In The 
M2 Domain Of The Acetylcholine-Receptor In Channel Gating. Molecular 
Pharmacology 48, 379-384 
16. Kearney, P. C., Zhang, H., Zhong, W., Dougherty, D. A., and Lester, H. A. (1996) 
Determinants of nicotinic receptor gating in natural and unnatural side chain 
structures at the M2 9’ position. Neuron 17, 1221-1229 
17. Labarca, C., Nowak, M. W., Zhang, H. Y., Tang, L. X., Deshpande, P., and 
Lester, H. A. (1995) Channel Gating Governed Symmetrically By Conserved 
Leucine Residues In The M2 Domain Of Nicotinic Receptors. Nature 376, 514-
516 
18. Zhong, W., Gallivan, J. P., Zhang, Y., Li, L., Lester, H. A., and Dougherty, D. A. 
(1998) From ab initio Quantum Mechanics to Molecular Neurobiology: A Cation-
$ Binding Site in the Nicotinic Receptor. Proc. Natl. Acad. Sci. (USA) 95, 12088-
12093 
19. Gleitsman, K. R., Shanata, J. A., Frazier, S. J., Lester, H. A., and Dougherty, D. 
A. (2009) Long-range coupling in an allosteric receptor revealed by mutant cycle 
analysis. Biophys J 96, 3168-3178 
20. Groot-Kormelink, P. J., Boorman, J. P., and Sivilotti, L. G. (2001) Formation of 
functional "3#4"5 human neuronal nicotinic receptors in Xenopus oocytes: a 
reporter mutation approach. British Journal of Pharmacology 134, 789-797 
21. Li, P., McCollum, M., Bracamontes, J., Steinbach, J. H., and Akk, G. (2011) 
Functional characterization of the "5(Asn398) variant associated with risk for 
nicotine dependence in the "3#4"5 nicotinic receptor. Molecular Pharmacology 
80, 818-827 
22. Papke, R. L., Sanberg, P. R., and Shytle, R. D. (2001) Analysis of Mecamylamine 
Stereoisomers on Human Nicotinic Receptor Subtypes. Journal of Pharmacology 
and Experimental Therapeutics 297, 646-657 
23. Lester, H. A. (1992) The Permiation Pathway of Neurotransmitter-Gated Ion 
Channels. Annual Review of Biophysics 21, 267-293 
24. Mu, T., Lester, H. A., and Dougherty, D. A. (2003) Different Binding 
Orientations for the Same Agonist at Homologous Receptors: A Lock and Key or 
a Simple Wedge? Journal of the American Chemical Society 125, 6850-6852 
25. Cashin, A. L., Petersson, E. J., Lester, H. A., and Dougherty, D. A. (2005) Using 
Physical Chemistry To Differentiate Nicotinic from Cholinergic Agonists at the 
Nicotinic Acetylcholine Receptor. Journal of the American Chemical Society 127, 
350-357 
26. Dougherty, D. A. (2008) Cys-Loop Neuroreceptors: Structure to the Rescue? 
Chemical Reviews 108, 1642-1654 
27. Puskar, N. L., Xiu, X., Lester, H. A., and Dougherty, D. A. (2011) Two Neuronal 
Nicotinic Acetylcholine Receptors, "4#4 and "7, Show Differential Agonist 
Binding Modes. Journal of Biological Chemistry 286, 14618-14627 
28. Tavares, X. D., Blum, A. P., Nakamura, D. T., Puskar, N. L., Shanata, J. A., 
Lester, H. A., and Dougherty, D. A. (2012) Variations in binding among several 
agonists at two stoichiometries of the neuronal, "4#2 nicotinic receptor. Journal 
of the American Chemical Society 134, 11474-11480 
*)!
29. Dougherty, D. A. (2013) The Cation-pi Interaction. Accounts of Chemical 
Research 46, 885-893 
30. Miwa, J. M., Freedman, R., and Lester, H. A. (2011) Neural systems governed by 
nicotinic acetylcholine receptors: emerging hypotheses. Neuron 70, 20-33 
31. Salas, R., Orr-Urtreger, A., Broide, R. S., Beaudet, A., Paylor, R., and De Biasi, 
M. (2003) The Nicotinic Acetylcholine Receptor Subunit "5 Mediates Short-
Term Effects of Nicotine in Vivo. Molecular Pharmacology 63, 1059-1067 
32. Wada, E., McKinnon, D., Heinemann, S., Patrick, J., and Swanson, L. W. (1990) 
The distribution of mRNA encoded by a new member of the neuronal nicotinic 
acetylcholine receptor gene family ("5) in the rat central nervous system. Brain 
Research 526, 45-54 
33. Exley, R., McIntosh, J. M., Marks, M. J., Maskos, U., and Cragg, S. J. (2012) 
Striatal "5 nicotinic receptor subunit regulates dopamine transmission in dorsal 
striatum. J Neurosci 32, 2352-2356 
34. Saccone, N. L., Saccone, S. F., Hinrichs, A. L., Stitzel, J. A., Duan, W., Pergadia, 
M. L., Agrawal, A., Breslau, N., Grucza, R. A., Hatsukami, D., Johnson, E. O., 
Madden, P. A. F., Swan, G. E., Wang, J., Goate, A. M., Rice, J. P., and Bierut, L. 
J. (2009) Multiple Distinct Risk Loci for Nicotinic Dependence Identified by 
Dense Coverage of the Complete Family of Nicotinic Receptor Subunit 
(CHRNA5) Genes. American Journal of Medical Genetics Neuropsychiatric 
Genetics, 453-467 
35. Bierut, L. J. (2010) Convergence of genetic findings for nicotine dependence and 
smoking related diseases with chromosome 15q24-25. Trends Pharmacol Sci 31, 
46-51 
36. Hartz, S. M., Short, S. E., Saccone, N. L., Culverhouse, R., Chen, L., Schwantes-
An, T. H., Coon, H., Han, Y., Stephens, S. H., Sun, J., Chen, X., Ducci, F., 
Dueker, N., Franceschini, N., Frank, J., Geller, F., Gubjartsson, D., Hansel, N. N., 
Jiang, C., Keskitalo-Vuokko, K., Liu, Z., Lyytikainen, L. P., Michel, M., Rawal, 
R., Rosenberger, A., Scheet, P., Shaffer, J. R., Teumer, A., Thompson, J. R., 
Vink, J. M., Vogelzangs, N., Wenzlaff, A. S., Wheeler, W., Xiao, X., Yang, B. Z., 
Aggen, S. H., Balmforth, A. J., Baumeister, S. E., Beaty, T., Bennett, S., Bergen, 
A. W., Boyd, H. A., Broms, U., Campbell, H., Chatterjee, N., Chen, J., Cheng, Y. 
C., Cichon, S., Couper, D., Cucca, F., Dick, D. M., Foroud, T., Furberg, H., 
Giegling, I., Gu, F., Hall, A. S., Hallfors, J., Han, S., Hartmann, A. M., Hayward, 
C., Heikkila, K., Hewitt, J. K., Hottenga, J. J., Jensen, M. K., Jousilahti, P., 
Kaakinen, M., Kittner, S. J., Konte, B., Korhonen, T., Landi, M. T., Laatikainen, 
T., Leppert, M., Levy, S. M., Mathias, R. A., McNeil, D. W., Medland, S. E., 
Montgomery, G. W., Muley, T., Murray, T., Nauck, M., North, K., Pergadia, M., 
Polasek, O., Ramos, E. M., Ripatti, S., Risch, A., Ruczinski, I., Rudan, I., 
Salomaa, V., Schlessinger, D., Styrkarsdottir, U., Terracciano, A., Uda, M., 
Willemsen, G., Wu, X., Abecasis, G., Barnes, K., Bickeboller, H., Boerwinkle, E., 
Boomsma, D. I., Caporaso, N., Duan, J., Edenberg, H. J., Francks, C., Gejman, P. 
V., Gelernter, J., Grabe, H. J., Hops, H., Jarvelin, M. R., Viikari, J., Kahonen, M., 
Kendler, K. S., Lehtimaki, T., Levinson, D. F., Marazita, M. L., Marchini, J., 
Melbye, M., Mitchell, B. D., Murray, J. C., Nothen, M. M., Penninx, B. W., 
Raitakari, O., Rietschel, M., Rujescu, D., Samani, N. J., Sanders, A. R., Schwartz, 
**!
A. G., Shete, S., Shi, J., Spitz, M., Stefansson, K., Swan, G. E., Thorgeirsson, T., 
Volzke, H., Wei, Q., Wichmann, H. E., Amos, C. I., Breslau, N., Cannon, D. S., 
Ehringer, M., Grucza, R., Hatsukami, D., Heath, A., Johnson, E. O., Kaprio, J., 
Madden, P., Martin, N. G., Stevens, V. L., Stitzel, J. A., Weiss, R. B., Kraft, P., 
and Bierut, L. J. (2012) Increased Genetic Vulnerability to Smoking at CHRNA5 
in Early-Onset Smokers. Archives of General Psychiatry 69, 854-861 
37. Frahm, S., %limak, Marta A., Ferrarese, L., Santos-Torres, J., Antolin-Fontes, B., 
Auer, S., Filkin, S., Pons, S., Fontaine, J.-F., Tsetlin, V., Maskos, U., and Ibañez-
Tallon, I. (2011) Aversion to Nicotine Is Regulated by the Balanced Activity of 
#4 and "5 Nicotinic Receptor Subunits in the Medial Habenula. Neuron 70, 522-
535 
38. George, A. A., Lucero, L. M., Damaj, M. I., Lukas, R. J., Chen, X., and 
Whiteaker, P. (2012) Function of human "3#4"5 nicotinic acetylcholine 
receptors is reduced by the "5(D398N) variant. J Biol Chem 287, 25151-25162 
39. Gotti, C., Moretti, M., Zanardi, A., Gaimarri, A., Champtiaux, N., Changeux, J. 
P., Whiteaker, P., Marks, M. J., Clementi, F., and Zoli, M. (2005) Heterogeneity 
and selective targeting of neuronal nicotinic acetylcholine receptor (nAChR) 
subtypes expressed on retinal afferents of the superior colliculus and lateral 
geniculate nucleus: Identification of a new native nAChR subtype "3#2("5 or #3) 
enriched in retinocollicular afferents. Molecular Pharmacology 68, 1162-1171 
 
  
*+!
 
 
Chapter 4 
 
 
Assay Development for Positive Allosteric Modulator Studies: 
Identification of Necessary Residues for Potentiation of  
Type I Modulators in !7 Nicotinic Acetylcholine Receptors 
 
 
 
4.1 Abstract 
 Nicotinic acetylcholine receptors (nAChRs) play vital roles in neuronal 
communication and are targets for neurological disorders. The "7 nAChR has been tied 
to schizophrenia and Alzheimer’s disease, which has resulted in a vast array of selective 
agonists. Over the last decade, research has increased on another class of compounds, 
positive allosteric modulators (PAMs). Allosteric modulators can influence physiological 
responses of the receptor when the natural neurotransmitter is present. However, our 
understanding of distinct structure-function relationships for these compounds is 
minimal. 
 This report involves modification of experimental methods for PAM potentiation 
measurements by introducing a temperature-controlling apparatus and using a new 
analysis method, charge integration, for the "7 receptor. This new assay was used to 
monitor mutagenesis effects on PAM potentiation. It was found that gain-of-function 
pore mutations greatly attenuate Type I PAM potentiation and that mutations in the 
transmembrane domain can reduce or eliminate these effects. These results suggests a 
different region, adjacent to Type II PAM binding, that is vital in Type I potentiation in 
*,!
the "7 receptor. Further research can provide mechanistic insight to the residues 
responsible for Type I and Type II PAM physiological differentiation. 
 
4.2 Introduction 
Neuronal nicotinic acetylcholine receptors (nAChRs) are a class of membrane 
proteins that belong to the Cys-loop superfamily of ligand-gated ion channels (LGICs). 
These receptors are composed of five subunits ("2-"7, "9, "10, or #2-#4) that can 
assemble homo- or heteromerically to form a pore that, when activated, allows cations to 
pass across the membrane (1-4). Ion permeability permits these receptors to play a large 
role in neuronal communication in the central nervous system (CNS). The diversity in 
receptor function and CNS distribution ties nAChRs to vital functions like memory and 
learning but also implicates them in neurological disorders such as addiction, 
Alzheimer’s disease, and Parkinson’s disease (2,4-8).  
The "7 nAChR is a unique homopentamer that is widely distributed throughout 
the brain and has been associated with neurological disorders such as schizophrenia and 
Alzheimer’s disease (9-16). In the case of Alzheimer’s disease, there are studies 
suggesting direct inhibition of function when associated with aggregated amyloid-# 
peptides (11,12). Discovering agonists that selectively activate the "7 receptor may be 
insufficient to reverse some of the effects associated with Alzheimer’s disease. In the last 
decade, more research has been dedicated to studying compounds that are positive 
allosteric modulators (PAMs) of "7 and other nAChRs (7,9,13,15,17-25). Allosteric 
modulators are compounds that bind to the protein at locations that are distant from the 
normal agonist binding pocket and change the receptor’s function without directly 
*-!
activating the receptor. The “positive” notion indicates a beneficial cooperativity in 
receptor function when a PAM and agonist are co-applied. Generally, an increase in 
current is observed upon co-application of a PAM with an agonist compared to the 
agonist alone. This can be represented by two functional changes: a decrease in 
EC50 values (gain-of-function) and/or a larger signal for all the doses of the original 
EC50 experiment (Figure 4.1). These two cases are not exclusive and both tend to affect 
EC50 curves (9,18,21,22). 
PAMs have received more attention as pharmaceutical targets because they have 
the potential to modulate receptor response without direct activation of the receptor. In 
addition, they have the potential to be more specific to receptor association, thus lowering 
side effects (9). Because of their potential in disease treatment, understanding where they 
bind and how they generate their effects is vital for further rational drug design. 
!
Figure 4.1 (A) Effects of PAMs on EC50 curves. There can be a gain-of-function (blue) 
or an increase in signal (red) relative to agonist alone (black). However most cases 
involve both changes and a hybrid curve is seen (purple). (B) Two classes of PAMs for 
"7 nAChRs. Type I (green) elicit only a change in peak height. Type II (brown) affect 
peak height, closure rates, and can reactivate the desensitized state. 
+.!
Currently, PAMs exist in two classes – Type I and Type II – and are separated according 
to the response they generate. Type I PAMs solely increase the peak current response, 
while Type II PAMs increase peak current response, drastically slow receptor closure 
rates, and can reactivate the desensitized state (Figure 4.1) (21). Numerous Type I and 
Type II PAMs have been developed for the "7 receptor. Probing for differences in 
structure-function relationships of the two types of PAMs would provide mechanistic 
insight to the distinct pharmacologies. 
This report focuses on assay development and subsequent investigation of Type I 
PAMs for the "7 receptor. Experimental protocols and data analysis were adapted and 
expanded upon by inclusion of a temperature control system and peak integration 
measurements. Conventional amino acid mutagenesis was employed to identify residues 
needed for PAM potentiation. These results show that gain-of-function pore mutations 
severely attenuate Type I PAM properties and can convert PAMs into negative allosteric 
modulators (NAMs). In addition, several new residues studied here showed reduction or 
elimination of Type I PAM potentiation.  
 
4.3 Results and Discussion 
4.3.1 Assay Development for PAM Measurements 
The first part of the report focuses on assay modification for consistent PAM 
signal potentiation. Type I PAMs have a singular effect in that they increase the signal 
response relative to the native agonist-only dose. These values are reported as a percent 
increase in peak height at a given agonist concentration. For these studies, we chose to 
use 100 µM acetylcholine (ACh) since it was close to most EC50 values for mutations. 
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This allowed for ample baseline signal while allowing room for signal to be potentiated. 
PAMs may decrease the barrier to reach the open-state equilibrium rather than change the 
equilibrium (or conductance) of open receptors at max concentrations. A shift in EC50 
without an increase in max signal when comparing the agonist alone vs. agonist/PAM 
co-application experiments would represent this phenomenon (Figure 4.1).  
The protocol outlined in Table 4.1 was the experimental procedure designed to 
measure percent change in peak height for PAMs (see 4.4.3 Methods for further 
information on experimental parameters regarding application durations and 
calculations). The first dose is ignored because the initial fluidics of the experiment can 
have a significant effect on receptor response. The initial dose allows the system to come 
to equilibrium in regards to small movements during the first drug application and buffer 
wash. Repetitive doses allow for averaging of both the agonist-only and agonist/PAM 
co-application signals. In addition, abnormal receptor responses can be identified and 
eliminated from analysis. Pre-incubation of the PAM prior to the agonist/PAM 
co-application permits the PAM to come to binding equilibrium to ensure maximal 
response measurements and serves as an internal control to ensure introduced mutations 
do change the compound’s profile from a PAM to an allosteric agonist (26,27). 
Subsequent doses of agonist only provide insight into the receptor’s ability to return to 
Table 4.1 PAM Potentiation Protocol 
Applications Notes Future Studies Adaptations 
100 µM ACh Ignore EC50 
100 µM ACh 
Average together 
EC50 
100 µM ACh EC50 
100 µM ACh and PAM 60 s pre-incubation, 
 co-application, and  
average together 
EC50 + PAM 
100 µM ACh and PAM EC50 + PAM 
100 µM ACh 
Average together 
EC50 
100 µM ACh EC50 
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pre-PAM applications and give a qualitative assessment of removal of the PAM 
compound from the oocyte. 
In the Dougherty lab, previous studies of the "7 receptor included a pore point 
mutation (T6’S) that slowed activation closure rates and desensitization. However, this 
mutation has large effects on PAM function (see section 4.3.2 below for discussion) and 
cannot be used for these studies. Removal of the T6’S mutation from the "7 receptor 
makes electrophysiological recording more challenging because of the dramatic increase 
in closure rates of activated receptors. Maximum peak current response can be variable 
because the electrophysiological recordings cannot reliably record the closure rates. 
Papke et al. has introduced a way to reduce this variability by integrating the current 
response over the drug application time period for a total charge value instead of a peak 
height measurement (28). As seen in Table 4.2, introduction of the integration analysis 
has reduced the relative percent error in the receptor responses. When applied to the dose 
response curves, a decrease in the EC50 value to values near the T6’S mutation values are 
observed (see Figure 4.2). This analysis retains the gain-of-function property of the T6’S 
and provides a way to compare waveform anomalies that sometimes occur during 
repetitive dosing (Figure 4.2). Due to the lack of literature for interpretation of total 
charge analysis from peak integration, comparisons of PAM potentiation will involve 
both peak height measurements and integration analysis in some cases. 
 
Table 4.2 Peak Height vs. Integration for PAM Potentiation 
  5-HI Relative Error 5-MI Relative Error 
"7WT:hRic3 
 
Max Peak 300 ± 40 13% 760 ± 100 13% 
Integration 450 ± 30 7% 2600 ± 100 4% 
"7 WT 
Max Peak 380 ± 40 11% 600 ± 60 10% 
Integration 480 ± 40 8% 2400 ± 150 6% 
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Figure 4.2 (A) Dose response curves for "7 T6’S:hRic3 and "7 WT:hRic3 using max 
peak current analysis and peak integration analysis. Integration of the peak response 
shifted the wild type (WT) receptor EC50 to a value comparable to the T6’S receptor. The 
variability between cell measurements that arises due to the fast desensitization of the 
receptor is reduced through this method of analysis. (B) Examples of ideal and abnormal 
"7 WT responses. The closure rate is extremely fast, and the electronics have issues 
measuring large current changes. These generate unusable waveforms for peak height 
analysis. However, integration can recover these waveforms since the total charge is 
being calculated. !
 
During experimental runs using the protocol outline in Table 4.1, an issue arose 
involving the measurements of receptor response to consecutive agonist-only doses. 
Comparing the signal response to identical agonist applications pre- and post-exposure to 
the PAM showed a steady increase in receptor response. In addition, replacing all steps 
with agonist only (and buffer for pre-incubation steps) showed a steady increase in signal 
despite the agonist applications being made of the same stock. The experiments were 
repeated at cooler temperatures (13-16°C) as opposed to room temperature (20°C) to 
solve the consistent signal increase. To achieve temperature control, a cooling unit (MGW 
Lauda-Brinkmann rm3) was adapted to the electrophysiology rig (See Figure 4.3). 
Roughly two feet of buffer lines were submerged in a second line containing salt/water 
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mixture, which was subsequently submerged into the cooling unit containing 100% 
isopropanol at a temperature of  -4°C to -6°C. Depending on flow rates, the buffer 
entered the oocyte chamber in the range of 13-16°C. Drug plates were kept on ice during 
washing steps to ensure an application temperature less than 15°C. These were more 
variable and ranged from 9-14°C, but the main goal of sub-15°C was consistently 
achieved. Temperature was monitored through a temperature-sensing adaptor for a 
multimeter (Fluke 116 HVAC Multimeter). Reduction of the experimental temperature 
can affect the two main sources of variability in these measurements: (1) the extremely 
fast desensitization of the receptor and (2) the steady increase in peak current over 
application of a constant concentration of agonist. Since the rates of conformational 
conversions are correlated with temperature, performing these experiments in a chilled 
buffer solution can slow conformational rearrangements and reduce some of the 
variability in the electrophysiological measurements. The steady signal increase can be 
attributed to the release of more vesicles containing receptors to the surface, which can  
 
!
Figure 4.3 Attached cooling unit. (A) Temperature measuring multimeter. (B) Cooling 
unit with submerged tubing. (C) Multimeter sensor in recording chamber. 
 
+)!
Table 4.3 Extracellular Mutations and Temperature Effects On Genistein 
Receptor w/ hRic3 Room Temperature (19-20°C) Cold Buffer Application (11-16°C) EC50 (µM) Hill % PAM Inc. EC50 (µM) Hill % PAM Inc. 
"7 WT 52 ± 2 2.1 ± 0.2 950 ± 260 32 ± 1 3.2 ± 0.2 120 ± 14 
"7 P83G 94 ± 3 1.9 ± 0.1 1400 ± 330 57 ± 6 3.0 ± 0.6 430 ± 30 
"7 K89A 40 ± 1 1.7 ± 0.1 1400 ± 300 24 ± 0.5 3.6 ± 0.3 320 ± 40 
"7 H107A 24 ± 2 1.6 ± 0.2 610 ± 80 15 ± 1 2.5 ± 0.2 290 ± 30 
"7 F126A – – – 5.5 ± 0.3 3.4 ± 0.5 130 ± 20 
"7 K127A – – – 15 ± 1 3.1 ± 0.5 230 ± 20 
"7 Y153A 70 ± 5 1.4 ± 0.1 1000 ± 160 32 ± 3 2.0 ± 0.3 240 ± 30 
"7 N173A – – – 62 ± 6 2.4 ± 0.5 200 ± 20 
"7 T201A – – – 164 ± 6 4.6 ± 0.4 730 ± 180 
Genistein = 10uM, All values are from integration data (no peak height analysis) 
Green = Arias et al. (33), Blue = Ludwig et al. (32) 
 
skew the data by causing a non-level baseline. Vesicle trafficking can be slowed and even 
halted by cooling the oocyte temperature to or below 15°C (29). An example comparing 
the effects of experiments performed at cooler temperatures can be seen in Table 4.3. 
There is a collective gain-of-function in regards to EC50 values. In addition, there is 
dampening of the percent PAM increases and reduction in relative percent error. 
The adaptations to the protocol and data analysis outline here greatly reduced the 
variability originally seen in initial measurements and provided reproducible 
measurements between repeated experiments. These PAM guidelines were used to 
further study mutational effects on a series of Type I PAMs outlined in the next section. 
PAM experiments in the future that utilize this protocol (Table 4.1) should change the 
concentration of agonist used for experiments. These studies used a single concentration 
of agonist (100 µM ACh) but use of the EC50 value for the mutation being probed would 
be more appropriate. This would provide a better comparison of PAM potentiation across 
mutations. Despite this observation, the experiments here still provide useful starting 
points and conclusions regarding Type I effects on the "7 receptor. The 
temperature-controlling unit was a novel attachment to the electrophysiology rig and 
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provided the first series of controlled temperature experiments for the Dougherty lab. It 
can be easily transcribed to other electrophysiology experiments (such as EC50 
experiments) and allows a new analysis for determining binding parameters not 
previously accessible from a single temperature study.  
 
4.3.2 Screening for Residues Essential in PAM Potentiation  
The second half of this report deals with identification of a PAM binding location 
on the rat "7 receptor and characterization of the important interactions for potentiation. 
As noted above, there are two classes of PAMs: Type I, which increase peak currents 
only, and Type II, which affect several parameters involved in activation, closure, and 
desensitization. Because Type I PAMs have a single effect on the "7 receptor, 
interpretation of the results remains simpler and allows easier identification of functional 
changes. Efforts toward the elucidation of Type I PAM potentiation on "7 are presented 
and discussed. 5-methoxyindole (5-MI), 5-hydroxyindole (5-HI), and genistein were the 
main probes in the structure-function studies of this report (Figure 4.4). 
The T6’S mutation had drastic effects on responses to 5-MI and 5-HI. The signal 
from co-application with 5-MI was severely attenuated and 5-HI was converted to a 
negative allosteric modulator (NAM). The T6’S mutation is located on the M2 helix of 
the receptor pore and has been used previously in "7 nAChR studies because it reduces 
the rate of desensitization and presents a gain-of-function (30). These properties allow 
more reliable current measurements at high agonist concentrations and a wider range to 
observe changes in EC50 values. Another factor to consider is the human Ric3 protein 
(hRic3), a trafficking protein that is routinely used to increase "7 receptor expression in 
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oocytes (31). In the present system, the presence of hRic3 had no meaningful effects on 
PAM potentiation measurements (Figure 4.4). Positive signal potentiation for 5-HI was 
recovered by reverting back to the original "7 wild type receptor, and 5-MI showed a 
dramatic increase in potency (Figure 4.4). Again, potentiation response was unaffected 
by the presence of hRic3, although receptor expression levels were generally higher 
while co-expressed with hRic3. These results suggest that further use of hRic3 for PAM 
studies is acceptable (and was included in further studies), while the T6’S mutation is 
detrimental. One possible explanation is that the T6’S mutation may act like a 
pseudo-Type II PAM itself because it affects receptor desensitization. Introduction of this 
pore mutation severely attenuates or even reverses Type I PAM current potentiation. 
 
Figure 4.4 PAM function is greatly influenced by the gain-of-function pore mutation 
T6’S. The hRic3 protein does not affect potentiation. (A) Type I PAMs 5-hydroxyindole 
(5-HI), 5-methoxyindole (5-MI), and Genistein (GEN). (B) PAM responses for the "7 
T6’S nAChR with and without hRic3. The agonist dose was 100 µM ACh and the PAM 
concentrations were all 1000 µM with a 60 s pre-incubation before co-application. 
(C) PAM responses for the rat "7 WT nAChR with and without hRic3. The agonist dose 
was 100 µM ACh and the PAM concentrations were all 1000 µM. Type I PAM properties 
are recovered. 
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Even though 5-MI and 5-HI give large potentiation, they require high doses 
(1 mM) to elicit potentiation, which is undesirable. Also, the chemical structures are 
small and provide minimal interactions to probe for structure-function relations. 
Genistein (a tyrosine kinase inhibitor, see Figure 4.4) has a larger structure capable of 
forming more binding interactions and has been shown to be a Type I PAM of the "7 
nAChR (21). Also, it has a potent signal potentiation at a smaller drug concentration 
(10 µM). These attributes led to a switch in compounds for further Type I PAM 
structure-function studies. 
At the time of these studies, several different sites were proposed for PAM 
binding or at least implicated as important for PAM potentiation in the "7 receptor. 
Several residues in various areas were mutated and put through our adapted 
methodology. Two different locations in the extracellular region were studied first. 
Ludwig et al. proposed a PAM binding site adjacent to the agonist-binding site (32), and 
Arias et al. proposed a PAM binding site on the opposite side compared to Ludwig’s 
proposal (See Figure 4.5) (33). Due to the disparity of these proposed binding sites, 
several residues from each location were probed through alanine-mutation screening. The 
mutations and integration analysis results for room temperature and 
temperature-controlled measurements are outlined in Table 4.3. These results suggest 
that residues K89 and Y153 do not play a role in genistein binding or its potentiation, 
because the EC50 values and the PAM percent increases are essentially the same as for the 
wild type receptor. Residues’ P83, H107, and Y153 effects are less clear due to the 
varying EC50 values and the lack in significant changes in PAM percent increase when 
compared to the wild type values. An important note, however, is that none of these 
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mutations dampened or eliminated the PAM response compared to the wild type receptor. 
The lack of a mutation that decreased or eliminated the PAM response suggests that these 
residues do not make direct interactions in PAM binding or influence its potentiation.  
The "7 receptor transmembrane region was probed next as it has been suggested 
to be the binding region for a Type II PAM, PNU-120596 (18,20,24). Several key 
residues were identified to be important in PNU-120596 action because of the 
significantly reduced peak potentiation: S245, A248, M276, F478, and C482 (numbering 
adjusted to full length "7 with the signaling sequence). These residues and several others 
surrounding this region were subjected to an alanine scan or the mutation used in 
previous studies (Table 4.4) (18,20,24). The first observation is that not all of the 
residues identified for PNU-120596 reduction decreased genistein potentiation. A248D 
and C482Y did not produce meaningful changes from the wild type response to genistein. 
Interestingly, C482Y had a large increase in potentiation, which is the opposite of what  
 
Figure 4.5 A homology model of two adjacent "7 subunits. (A) The binding site 
proposed by Ludwig et al. is colored in blue (32). The binding site proposed by 
Arias et al. is colored in cyan (33). The aromatic box (agonist binding pocket) is in 
magenta. (B) The binding site proposed by Young et al. is colored in brown (24). These 
residues are situated between the four transmembrane "-helices of one subunit. Several 
residues from all sites were studied. 
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Table 4.4 Transmembrane Mutations For Genistein 
"7 n 
EC50 (µM) %PAM Increase 
Peak Area Peak Area 
Wild Type 11/16 274 ± 7 78 ± 5 360 ± 40 500 ± 50 
G175K* 7/11 17 ± 2 3.3 ± 0.2 80 ± 20 150 ± 20 
Y232A 6/4 No expression No expression 
N236A 19/10 300 ± 8 54 ± 5 7 ± 8 20 ± 8 
C241A 7/5 224 ± 10 71 ± 2 -26 ± 5 -33 ± 6 
S245A 7/7 – – 50 ± 15 220 ± 20 
A248D 3/3 – – 250 ± 30 830 ± 100 
T267A 5/5 42 ± 1 18.3 ± 0.6 20 ± 3 80 ± 6 
S271A 5/6 204 ± 9 51 ± 3 170 ± 40 170 ± 40 
F275A 5/5 300 ± 15 47 ± 6 66 ± 12 110 ± 20 
M276L 6/6 93 ± 6 35 ± 1 -5 ± 10 -1 ± 8 
M283A,T6'S 5/7 1800 ± 100 920 ± 90 280 ± 30 240 ± 14 
S287A 10/4 38 ± 3 20 ± 1 30 ± 10 30 ± 6 
D288A,T6'S 4/6 740 ± 40 410 ± 20 14 ± 7 3 ± 11 
S289A 6/6 – – 310 ± 40 70 ± 10 
F297A 6/6 – – 440 ± 50 490 ± 40 
T300A 3/3 – – 650 ± 200 1650 ± 400 
M301A 6/7 19 ± 1 10.1 ± 0.3 0.6 ± 5 -26 ± 6 
F475A 5/5 – – 570 ± 80 1500 ± 200 
F478A 13/13 – – 110 ± 10 310 ± 25 
C482Y 5/5 – – 2600 ± 600 1900 ± 400 
*Extracellular mutations 
Cold Buffer (11-16°C), hRic3 used with receptor 
 
was expected. Also, F478A and S245A only had minimal reduction in potentiation 
strength. Larger effects were found for residues that were above the proposed 
PNU-120596 binding site and closer to the extracellular domain (Figure 4.6). The most 
distinct mutation involved the N236A, which showed nearly identical waveforms 
whether genistein was present or not (Figure 4.7). These residues comprise a different 
location that spans the interface of two subunit transmembrane regions and lies closer to 
the extracellular region. Since Type I PAMs have different pharmacology properties from 
Type II PAMs, it is not unreasonable to conclude they bind in a similar region close but 
not identical to each other. Even though loss of potentiation has been used previously to 
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probe for PAM binding, it is not a definitive measurement since potentiation loss is seen 
for a gain-of-function mutation found in the extracellular region adjacent to the agonist 
binding site (Table 4.4). However, it still provides important structure-function 
observations. 
Another notable residue involved M301A, which resides on the M3 "-helix. A 
large gain-of-function is seen in the EC50 as well as a drastic change in receptor closure 
rates (Table 4.4 and Figure 4.7). This is interesting because mutations affecting 
desensitization of "7 receptors typically lie on the M2 "-helix. In addition, application of 
a Type I PAM (genistein) seems to speed up the receptor closure. M301 resides at the 
bottom of a potential methionine stack that includes M276 (M2 "-helix) and 
 
Figure 4.6 Homology model of "7 transmembrane region (A) Residues probed that 
showed a reduction in genistein potentiation. Residues (green) are labeled as well as the 
transmembrane helices (two adjacent subunits labeled as red and cyan). Purple residues 
(T267A and M301A) had large changes in receptor closure rate. (B) Three methionine 
residues that are vertically stacked in a single subunit. 
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M283 (M2-M3 loop) (Figure 4.6). Methionine residues have been shown to form 
stabilizing interactions with aromatic groups (34), but they have also been shown to be 
destabilizing when buried inside the hydrophobic region of a protein (35). Removal of 
this methionine (301) may release steric interactions that are generated with M2 "-helix 
movement during receptor activation. This mutation warrants further investigation for use 
in "7 receptor structure-function studies like the previously used T6’S pore mutation. 
 
 
 
Figure 4.7 Sample traces from PAM potentiation experiments run at colder temperatures. 
Blue boxes represent genistein (GEN) duration and green represents acetylcholine (ACh). 
Left: wild type (WT) responses show clear potentiation when genistein is present. Right: 
two mutation results. N236A shows the most drastic elimination of genistein potentiation. 
M301A had a drastic effect on the receptor’s closure rate when exposed to acetylcholine 
only. It also fully eliminated genistein potentiation. 
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4.4 Conclusions 
 Research towards understanding and development of allosteric modulators has 
increased due to several beneficial properties for disease treatment. This study focuses on 
identifying structure-function relationships of Type I PAMs in "7 nAChRs. An adapted 
experimental protocol and analysis method was established to increase reproducibility 
and consistency in potentiation measurements. The electrophysiology rig was modified 
with a temperature-control device to improve response drifts during experiments. Charge 
integration was introduced alongside peak height analysis to identify mutations that affect 
receptor potentiation from allosteric modulators. Then, mutation screening in several 
proposed PAM binding pockets was performed on the "7 receptor. Type I PAMs (5-HI 
and 5-MI) were unaffected by several mutations in the extracellular domain, which 
suggests a transmembrane binding region. Residues linked to PNU-120596 (Type II 
PAM) binding and those around the site were probed using the Type I PAM genistein. 
These results reveal that not all residues tied to PNU-120596 binding resulted in a 
decrease in genistein potentiation. Several new residues closer to the extracellular domain 
had a larger effect and even eliminated genistein potentiation. These residues are found at 
the interface of M1 and M2 transmembrane "-helices of one subunit and M2 and M3 
"-helices of the adjacent subunit. This resembles interfacial agonist binding in the 
extracellular region. Even though this is not definitive in identifying a binding site, it 
strongly suggests these residues are vital in transmission of PAM potentiation during 
receptor activation. In addition, Type I and Type II PAMs may interact with similar 
residues, but they are not all the same. Further investigation into these differences would 
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aid in our understanding of PAM type differentiation and the influences by which they 
propagate their modulation.  
 
4.5 Methods 
 
4.5.1 Molecular Biology and Homology Models 
The "7 and hRic3 plasmids were in the pAMV vector provided by Nyssa Puskar 
and Walrati Limapichat. Mutations to these receptors were accomplished through 
site-directed mutagenesis using the QuikChange protocol (Stratagene). The NotI 
restriction enzyme was used for linearizing the "7 and hRic3 plasmids. Post linearization 
and purification (Qiagen), mRNA was synthesized through run-off transcription by using 
Ambion’s T7 mMessage Machine kits. Purification of the transcribed mRNA was 
performed using Qiagen’s RNeasy RNA kit. 
Residue numbering was based on the full-length protein containing the signaling 
sequence as found on the Ligand Gated Ion Channel Database. The figures were 
generated using PyMOL and a homology model (generated via MODELLER) of the rat 
"7 receptor based on the GluCl crystal structure (PDB 3RHW). 
 
4.5.2 Injection of Oocytes and Chemical Preparation  
Xenopus laevis stage V and VI oocytes were harvested via standard 
protocols (36). "7 and hRic3 mRNA were pre-mixed in a 1:1 ratio for a concentration of 
0.8 ng of total mRNA per µL. 50 nL were injected per oocyte to deliver 40 ng total of 
mRNA per cell. For "7 only, 20 ng of mRNA was injected per oocyte. Injected cells 
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were incubated for 24-72 hours. All cells were incubated at a temperature of 18°C in 
ND96+ media. 
5-hydroxyindole (5-HI) and 5-methoxyindole (5-MI) were purchased from 
Combi-Blocks Inc. 4’,5,7-Trihydroxyisoflavone (genistein) was purchased from Alfa 
Aesar. Acetylcholine (ACh) was purchased from Sigma-Aldrich. 5-HI, 5-MI, and 
genistein were dissolve in DMSO for stock solutions. These were then diluted to proper 
experimental concentrations in buffer with 0.1% v/v DMSO. 
 
4.5.3 Electrophysiology  
Electrophysiology recordings were performed using a two electrode voltage 
clamp technique with the OpusXpress 6000A (Axon Instruments). ND96 w/ Ca2+ 
(96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2 at pH 7.5) was 
used as the recording buffer. Solution washout rates were 4 mL/min for the first 30 s and 
then 3 mL/min for the continued duration. Drug applications were 4 mL/min for 15 s. 
Holding potentials were –60 mV for all cells. Data was collected at 125 Hz and filtered at 
50 Hz.  
For all "7 experiments, the wash time between drug application doses totaled 
5 min. EC50 dose response curves were obtained by applying increasing drug 
concentrations for 15 s (1 mL application total always) with appropriate wash out times. 
The resulting data was then fit to the Hill equation, Inorm = 1/[1+(EC50/A)]nH, where Inorm 
is the normalized current at a designated agonist concentration, A; EC50 is the agonist 
value that produces half maximal response; nH is the Hill coefficient. Averaging 
normalized cell response and then fitting to this equation produced the reported EC50 
,*!
values. For the PAM experiments (Table 4.1), the same washing protocols were 
performed and 100 µM ACh was used as the agonist. The PAM experiment protocol was 
as follows: first three doses (dose one is ignored in analysis) were of a constant ACh 
concentration and washout; two 1 mL doses of PAM only were applied without washout 
followed immediately with an application of a mix of ACh and PAM followed by 
washout, which was repeated twice; the final two applications were of a constant ACh 
concentration and washout. All currents were normalized to the highest response 
pre-PAM addition. PAM percent increases were calculated by averaging the first two 
ACh-only responses and the two ACh/PAM co-application responses. The difference 
between the two values was then taken and multiplied by 100%.  
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Chapter 5 
 
 
An Unaltered Orthosteric Site and a Network of Long-Range Allosteric 
Interactions for PNU-120596 in !7 Nicotinic Acetylcholine Receptors* 
 
 
*This chapter is adapted from: Christopher B. Marotta, Henry A. Lester, and Dennis A. 
Dougherty. An unaltered orthosteric site and a network of long-range allosteric 
interactions for PNU-120596 in "7 nicotinic acetylcholine receptors. This paper has been 
submitted to Chemistry and Biology for consideration. The work described in this chapter 
was done in collaboration with Dr. Henry Lester and Dr. Dennis Dougherty. 
 
5.1 Abstract 
 Nicotinic acetylcholine receptors (nAChRs) are vital to neuronal signaling, are 
implicated in important processes such as learning and memory, and are therapeutic 
targets for neural diseases. The "7 nAChR has been implicated in Alzheimer’s disease 
and schizophrenia, and allosteric modulators have become one focus of drug 
development efforts. We investigate the mode of action of the "7-selective positive 
allosteric modulator, PNU-120596, and show that the higher potency of acetylcholine in 
the presence of PNU-120596 is not due to an altered agonist binding site. In addition, we 
propose several residues in the gating interface and transmembrane region that are 
functionally important to transduction of allosteric properties and link PNU-120596, the 
acetylcholine binding region, and the receptor’s gate. These results suggest global protein 
stabilization from a communication network through several key residues that alter the 
gating equilibrium of the receptor while leaving the agonist binding properties 
unperturbed. 
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5.2 Introduction 
 Nicotinic acetylcholine receptors (nAChRs) are pentameric ion channels that are 
part of the Cys-loop superfamily of ligand-gated ion channels, which includes receptors 
gated by other neurotransmitters such as glycine, serotonin, and GABA. The "7 nAChR 
is comprised of five identical subunits that each contain an extracellular domain, 
transmembrane domain, and a gating interface (Figure 5.1) (1-3). This receptor subtype 
is uncommon among nAChRs in its ability to form homopentamers, and it displays a 
large and dispersed presence throughout the central nervous system (CNS) (4).  
The concepts of allostery, including cooperative transitions between two states of 
multisubunit proteins (5), have been applied to nAChRs in two ways. First, the nAChR 
itself has been identified as a protein containing two distinct domains, a binding site for 
agonists and a conducting pathway (6,7). The existence of one or more additional, 
desensitized, states was recognized early on (8,9). 
Second, and more relevant to the present study, compounds have been identified 
that do not produce activation on their own, yet modulate activation and desensitization, 
and bind at sites distinct from both the agonist site (the “orthosteric” site) and channel 
pore. These are allosteric ligands. At "7 nAChRs, positive allosteric modulators (PAMs) 
are especially well studied, and two classes can be distinguished.  Type I PAMs increase 
agonist-induced activation.  Type II PAMs, such as PNU-120596 (Figure 5.1), increase 
agonist-induced activation and also vastly prolong the waveform of agonist-induced 
currents; in the usual interpretation, PAMs favor the active states at the expense of the 
desensitized states (Figure 5.1) (10-15).  
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Figure 5.1 Homology model of the rat "7 nAChR. (A) This ligand gated ion channel 
consists of five subunits arranged in a pentameric fashion, which forms a pore to transmit 
cations across the membrane. Each subunit consists of a large extracellular domain where 
the agonist binding site lies between two subunits. In addition, there is a transmembrane 
region consisting of four "-helices and an intracellular portion used for receptor 
trafficking (not shown). The region where the extracellular domain and transmembrane 
physically interact is considered the gating interface and is thought to be important for 
signal relay from the agonist binding site to the channel gate (33,34). (B) Chemical 
structures of acetylcholine and PNU-120596. (C) Sample traces of "7 receptor responses 
for wild type and the cases designated “FAST” and “SLOW” decay currents in Table 5.4. 
Acetylcholine is represented by a black bar and 10 µM PNU-120596 is represented by a 
checker-pattern bar. EC50 doses of acetylcholine were used for each respective mutation. 
For the Y232F mutation in the absence and presence of PNU-120596, both traces show 
fast decay currents, which closely resembles the wild type response. For the M276L 
mutation however, the starting acetylcholine application has slowed decay current, which 
is further amplified when PNU-120596 is introduced. 
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Inherent to models of allostery is the notion of action at a distance, and it is of 
interest to ask whether the orthosteric binding site, and/or the channel pore, is affected by 
the presence of an allosteric modulator. Unfortunately no atomic-scale structural 
information is available for full "7 nAChRs in any state, let alone all three states in the 
presence of either an agonist or allosteric modulator. However, the high functional 
resolution of electrophysiological data allows other approaches to this question. For 
example, the structurally unrelated allosteric modulator 4PB-TQS has been shown to 
change the kinetics of gating as well as single-channel conductance of "7 nAChRs (16), 
indicating that an allosteric modulator can change the structure of the conducting pore. 
This study begins by determining to what extent, if any, an allosteric modulator 
changes the orthosteric site (Figure 5.2). Previous data suggested that an allosteric 
modulator can affect residues within the extracellular domain, but outside the orthosteric 
site itself (17). Non-canonical amino acid mutagenesis provides high-resolution data that 
complement those from X-ray crystallography. The key binding interactions at the 
agonist binding site of nAChRs – a cation-' interaction and two hydrogen bonds – are 
both sensitive to ligand displacements of <1 Å (18-20). We have therefore applied 
non-canonical amino acid mutagenesis to ask whether the presence of a PAM in any way 
modulates these binding interactions at the orthosteric site. The crucial point is that the 
non-canonical amino acid methodology is sensitive enough to detect even small changes 
in specific interactions. 
Our next goal was to map out the functional coupling pathway from the 
orthosteric site to the allosteric binding site of PNU-120596 – which is thought to be in 
the transmembrane region (21,22) – and/or from the allosteric site to the channel gate. 
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We term our strategy, which again uses functional measurements, “double perturbation 
cycle analysis” (see Figure 5.3). In this analysis, the first perturbation is mutation of the 
protein (with conventional or non-canonical amino acids); and the second perturbation is 
not a mutation, but the addition of PNU-120596. Non-additivity of the two perturbations 
indicates that the protein mutation differentially impacts receptor function depending on 
whether PNU-120596 is or is not present, suggesting that the residue under study plays 
an important role in allosteric modulation (23-25).  
From these studies, we have identified several residues with significant ))G 
values, suggesting a potential pathway of communication from the agonist binding site to 
the PAM binding site and then on to the receptor gate. 
 
 
 
Figure 5.2 Agonist binding site for the "7 nAChR. Several tyrosine and tryptophan 
residues comprise the aromatic box for the agonist binding site. These residues are 
labeled thus: TyrA (Y115), TrpB (W171), TyrC1 (Y210), and TyrC2 (Y217) lie on the 
principal side (cyan) of one subunit while TrpD (W77) lies on the complementary side 
(magenta) of the adjacent subunit. Backbone hydrogen bonding interactions have been 
implicated for the carbonyl of TrpB and the backbone amide of Leu141. Residues that 
have been shown to turn PNU-120596 into a weak agonist – Leu60, Asn75, and TrpD – 
have been highlighted to show the proximity to and inclusion of (in the case of TrpD) the 
aromatic box. 
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Figure 5.3 Example of the double 
perturbation cycle analysis. ACh = 
acetylcholine; PNU = PNU-120596. By 
keeping one of the “mutations” as the 
addition of PNU-120596, residues that are 
important for allosteric propagation through 
the protein can be assessed by generating a 
))G of greater than 0.5 kcal/mol. Here, the 
equation for generating ))G values is 
shown along with two mutations – one that 
is coupled and one that is not – as an 
example of the non-additivity and basis for 
this report’s functional coupling 
comparisons. Room temperature (25°C) was 
used for the value, T. 
5.3 Results 
5.3.1 Methodology for Interpretation of Functional Coupling Comparisons 
As noted in the Introduction, we sought to identify mutations of the receptor that 
differentially impact function when PNU-120596 is or is not present. Since we wish to 
evaluate a large number of sites throughout the protein, our metric is EC50, rather than 
more tedious single-channel methods. We fully appreciate the composite nature of EC50, 
and have in fact used it to our advantage in evaluating an allosteric modulator. 
One can envision two limiting modes of allosteric activation for a ligand-gated 
ion channel. Binding of the modulator could induce a conformational change in the 
protein that propagates to the orthosteric site, altering the innate affinity of that site for 
the natural agonist. Alternatively, the allosteric modulator could impact the gating 
transition of the receptor, by binding essentially at the metaphorical “gate” or, again, by 
action through a distance.  
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We have developed a strategy to distinguish these two possibilities and, in so 
doing, have removed ambiguities associated with EC50 measurements. Beginning in 
1995, we have developed methods for probing structure-function relationships at the 
agonist binding site of nicotinic receptors and related proteins with unprecedented 
precision. Using non-canonical amino acids, we can reveal key drug-receptor contacts. 
We can identify cation-' interactions using fluorination, and we can evaluate potential 
hydrogen bonding interactions using backbone mutagenesis. Importantly, both 
approaches provide information on the magnitude of the non-covalent interaction 
between drug and receptor. As such, we can detect subtle changes in the agonist binding 
site that would enhance (or diminish) agonist binding in ways that are just not possible 
with conventional approaches. As described below, we find no evidence of alteration of 
the agonist binding site on addition of PNU-120596. 
EC50 describes a composite of several equilibria, some involving agonist binding, 
some involving channel gating. Since we can rule out alteration of binding equilibria, we 
can conclude that changes in EC50 induced by PNU-120596 reflect changes in the gating 
equilibria of the receptor. We have used such analyses before, removing the innate 
ambiguity in EC50 by eliminating one component of the measurement (26,27).  
Again, our goal is to identify residues that play a role in the allosteric modulation 
provided by PNU-120596. To do this, we compare the impact of a mutation on wild type 
function vs. function when PNU-120596 is present. If the mutation does not affect 
PNU-120596 in any way, the mutation’s impact should be the same whether 
PNU-120596 is present or not. Stated differently, the impacts on wild type EC50 of the 
mutation and of PNU-120596 should simply have additive energies.  Alternatively, if a 
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mutation alters PNU-120596 function, then the effect of PNU-120596 on receptor 
function should be different from wild type when the mutation is present. That is, the side 
chain mutation and the impact of PNU-120596 should be non-additive. By analogy to 
conventional double mutant cycle analysis, the non-additivity can be expressed as a ))G 
value (Figure 5.3), which, if markedly different from zero, signifies the presence of 
non-local conformational effects on a large and complex membrane bound protein.  
 
5.3.2 The Orthosteric Site:  Binding Interactions are Unaffected by PNU-120596 
Previous studies of the "7 nAChR show that acetylcholine makes a single 
cation-' interaction with TyrA (Figure 5.2), which is one of five aromatic residues at the 
orthosteric binding site (28). One possible way in which the allosteric binding of 
PNU-120596 could impact receptor function is by influencing the shape of the aromatic 
box, such that the strength of the cation-' interaction to acetylcholine could change, or 
the site of the cation-' interaction could move to another aromatic residue instead of or in 
cooperation with TyrA. Other studies show that mutations outside the agonist binding site 
can reshape the binding site and significantly alter agonist-receptor contacts (27). One 
can identify cation-' interactions using progressive fluorination of the aromatic groups 
that contribute the ' electrons. We were able to probe four of the five aromatic box 
residues for acetylcholine cation-' interactions in the absence and presence of 
PNU-120596 (Table 5.1) (See Figure 5.4 for structures). TyrC1 could not be probed 
because of the large loss of function for any substitution made at this residue; TyrC1 has 
never been implicated in a cation-' interaction in the dozens of studies of Cys-loop 
receptors we have performed (18).  
-,!
 
Figure 5.4 Chemical structures of the non-canonical amino acid used to probe the agonist 
binding site. 
 
The first observation is that acetylcholine continues to make a cation-' interaction 
with TyrA in the presence of PNU-120596 (Fig. 5.5). In addition, the slopes of the two 
fluorination plots (with and without PNU-120596) are not meaningfully different, which 
indicates that the strength of the cation-' interaction was also unaltered (18). Since the 
interaction with TyrA was unchanged, TyrC2 was probed next, because previous data 
show that a higher sensitivity agonist – epibatidine – makes a cation-' interaction with 
TyrC2 in addition to TyrA in the "7 nAChR (28). As seen in Figure 5.5, a cation-' 
interaction still does not exist between TyrC2 and acetylcholine in the presence of 
PNU-120596. However, two observations can be made regarding interactions with the 
TyrC2 residue. The near wild type receptor response for bulky substituent groups 
(4-CN-Phe, 4-Br-Phe, and TyrOMe) and severe loss of function for small/no substituents 
(4-F-Phe and Phe) suggest a large substituent is needed at the 4-position in the aromatic 
ring to maintain proper receptor function. In addition, the receptor cannot tolerate 
substitutions at the 3- or 5-position in the ring system, as indicated by the large loss of 
function for 3-F-TyrOMe and 3,5-F2-TyrOMe residues. These results suggest a tight 
b
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steric environment for TyrC2 at the orthosteric site. Of more relevance here, however, is 
the fact that the pattern of responses to substitution at TyrC2 is unaltered by the presence 
of PNU-120596. 
 
Figure 5.5 Cation-' plots for TyrA and TyrC2 in the rat "7 receptor. 
ACh = acetylcholine; PNU = PNU-120596. The agonist binding site consists of five 
aromatic residues, four of which are on the primary subunit and one of which is on the 
complementary subunit. Previously, TyrA has been shown to make an interaction with 
acetylcholine and TyrC2 with epibatidine, a more potent partial agonist (28). (A) The 
cation-' interaction is present at TyrA and does not shift in its relative strength when 
PNU-120596 is added. (B) TyrC2 shows no cation-' interaction with acetylcholine, even 
in the presence of PNU-120596. These data suggest that the agonist binding site is not 
being reshaped from the presence of an allosteric modulator and the effects observed with 
PNU-120596 reside in altering the protein elsewhere. 
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Since PNU-120596 did not influence the two critical Tyr residues in the "7 
nAChR, the Trp residues were also studied. Note that for most combinations of agonist 
and nAChR, the cation-' interaction is to TrpB; "7 is unusual in employing TyrA. For 
both TrpB and TrpD, in the presence and absence of PNU-120596, there was not a 
meaningful shift in function when we expressed the highly perturbing residue 
4,5,6,7-F4-Trp (Table 5.1). This indicates that acetylcholine is not making a cation-' 
interaction with either of these residues. Previous studies showed that a much more 
dramatic mutation of TrpD – to Ala – converted PNU-120596 into a partial agonist, while 
maintaining its function as a positive allosteric modulator (17,29). We find that this 
mutation shows a ))G of essentially zero (Table 5.1).  
We also applied a previously described strategy for evaluating the two key 
H-bonding interactions previously established at the agonist binding site (19,20). Briefly, 
"-hydroxy analogues of "-amino acids are incorporated in ways that are known to 
strongly modulate the hydrogen bonding ability of the protein backbone. We found that 
perturbation of the hydrogen bond acceptor (L141) or the hydrogen bond donor (S172) 
had little impact on PNU-120596 modulation (Figure 5.2) (Table 5.2).  
Overall, the high-precision methodology of non-canonical amino acid 
mutagenesis allows us to conclude that the presence PNU-120596 does not measurably 
alter the key binding interactions to ACh at the orthosteric site.  
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5.3.3 A Double Perturbation Cycle Analysis to Identify Residues Critical to PNU-120596 
Function 
We assessed numerous residues throughout the "7 subunit to determine whether 
they played a role in the allosteric modulation by PNU-120596. Previous studies have 
emphasized how mutations impact the potentiation produced by PNU-120596, an 
approach that has produced useful insights such as identification of the PNU-120596 
binding site in the transmembrane region. We extended previous data by adopting the 
double perturbation cycle analysis, which is appropriate for identifying long-range 
communication between two sites of interest (described in Figure 5.3). Results are 
tabulated for all residues studied in Tables 5.1, 5.2, and 5.3. If the absolute value of the 
calculated ))G is & 0.5 kcal/mol, we consider the protein residue to be functionally 
important to the allosteric modulatory activity of PNU-120596. This approach may 
minimize possible complications arising from changes to the receptor that do not 
influence the allosteric communication pathway. (23). 
Previous experiments probing agonist-binding interactions in "7 nAChRs were 
aided by the inclusion of a pore mutation (T6’S) that produces a modest gain of function 
and slows "7 desensitization, allowing more precise waveform analysis (19,28). 
However, this mutation is coupled to PNU-120596, with a ))G of 0.68 kcal/mol. As 
such, this mutation was disregarded for the majority of this study except in two cases 
where the introduced mutations generated a non-functional receptor that was recoverable 
through the introduction of a gain-of-function pore mutation (30). 
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5.3.4 Measuring the Coupling at the Proposed PNU-120596 Binding Site   
 Several studies of the impact of mutations on PNU-120596 potentiation of 
acetylcholine response suggested that PNU-120596 binds in the transmembrane region, 
across "-helices M1 (S245 & A248), M2 (M276), and M4 (F478 & C482) of a single 
subunit (Figure 5.6) (22,31). Since the goal of the present work was to map out the 
functional coupling pathway between the binding site for PNU-120596 and the agonist 
binding site, we mutated a large number of residues throughout the receptor (Tables 5.1, 
5.2, 5.3). For purposes of discussion, we will begin at the “bottom” and work our way up 
to the agonist binding site. 
Of the five residues thought to contribute to the PNU-120596 binding site, only 
two show a meaningful functional coupling. However, several nearby residues did show 
meaningful coupling (Table 5.3). Interestingly, these residues generally lie “above” the 
three residues that were previously implicated in binding but show no coupling (A248, 
F478, C482). Further exploration of the area around this region yielded several other 
residues – C241 (M1), F275 (M2), and M301 (M3) – that resulted in a large coupling, as 
reflected in the ))G values. As seen in Figure 5.6, these residues lie outside the 
previously proposed PNU-120596 binding pocket (32). 
Some of these residues produced interesting response waveforms. F275A showed 
responses that – regardless of the addition of PNU-120596 – resembled wild type "7 
acetylcholine waveforms. Conversely, M276L and M301A provided the opposite 
observation for the decay phase: they showed a slowed response whether PNU-120596 
was added or not.  
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Figure 5.6 Summary of residues that generated a ))G greater than 0.5 kcal/mol for the 
functional coupling comparison or caused PNU-120596 to become a weak agonist. Only 
two subunits are shown for clarity. The color scheme is as follows: magenta, 
PNU-120596 becomes a partial agonist; orange, T6’S on the M2 helix; blue, new 
residues discovered to have a ))G & 0.5 kcal/mol; green, residues previously studied that 
also show a ))G & 0.5 kcal/mol; yellow, residues previously implicated in the 
PNU-120596 binding site that do not show a ))G & 0.5 kcal/mol. 
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5.3.5 Important Residues in the Gating Interface and the Extracellular Domain 
Previous cysteine labeling experiments by Barron et al. showed several 
extracellular residues positioned at the interface of two adjacent subunits that underwent 
conformational changes in the "7 nAChR when exposed to either PNU-120596 or 
acetylcholine (17). These residues (L60, M63, E67, N75, N193, and E195) were 
evaluated along with several others in the surrounding region (Table 5.2). Figure 5.6 
shows the residues in the gating interface with ))G & 0.5 kcal/mol (33,34). Tillman et al. 
showed, through chimera analysis, that specific loops and linkers were necessary for 
PNU-120596 potentiation of "7 receptors (34). Here, we were able to isolate specific 
residues on some of these identified regions: in Loop 2, E67; in Loop 9, E195; and in the 
M2-M3 Linker, S287. Again, we observed distinct response waveforms. Results for 
E67A/N, E195A, Y232F, N236A, and S287A all resembled "7 wild type acetylcholine 
waveforms, even in the presence of PNU-120596 (Figure 5.1 and Table 5.4). 
All the mutations that had markedly affected ))G, or that rendered PNU-120596 
an agonist, define a network of residues necessary for propagation of the PNU-120596 
effects throughout the full receptor (Figure 5.6). In addition, this can suggest a 
conformational wave of movement upon activation and gives insight into the molecular 
motions that potentially take place between the closed and open forms of the receptor. 
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5.4 Discussion 
 The present work aims to evaluate the influences of the positive allosteric 
modulator PNU-120596 on "7 nAChRs. Through the use of non-canonical amino acids, 
the binding region of acetylcholine was probed for potential changes in interactions with 
acetylcholine when PNU-120596 was introduced. These studies produced three key 
results: 1) the cation-' interaction with the TyrA residue is not perturbed by the 
introduction of PNU-120596, 2) no other cation-' interactions are gained when 
PNU-120596 is present, and 3) the overall shape of the agonist binding site seems 
unperturbed. The aromatic fluorination series and introduction of "-hydroxy acid 
residues give compelling evidence that no significant rearrangements propagate to the 
orthosteric binding site from the allosteric binding site of PNU-120596.  
Since no distinct change to the agonist binding motif was observed, we suggest 
that PNU-120596 does not alter the binding step of the agonist to the receptor and instead 
exerts its effects only on the gating equilibrium. As explained above, this result 
effectively removes the ambiguity in comparing EC50 values for various mutations.  
Since the agonist binding site is unperturbed, it is reasonable to assume that PNU-120596 
primarily, if not solely, influences receptor function by perturbing gating equilibria. The 
binding of PNU-120596 apparently impacts important residues required for signal 
transduction from the agonist binding site to the channel gate. In evaluating long-range 
interactions between residues, functional coupling comparisons based on a double 
perturbation cycle analysis provide an appropriate and rigorous method (23-25). The 
functional coupling comparisons were used to probe for mutations that coupled 
acetylcholine and PNU-120596 together, thus allowing for identification of residues 
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necessary for proper PAM function and influence. Table 5.4 summarizes the major 
observations and results of this study. Figure 5.7 shows the fold shift data from Tables 
5.1, 5.2, and 5.3 in a graphical form, which supports the analysis of the double 
perturbation cycle. The non-additive mutations do not adhere to the linear relationship 
seen with the those that do not influence PNU-120596 effects. From these data, several 
observations and conclusions can be drawn to elicit new information on allosteric 
modulation of "7 nAChRs by PNU-120596. 
An interesting observation concerned the mutations M276L and M301A, which 
changed the decay current rate of acetylcholine-only waveforms (Table 5.4). This effect 
is quite similar to that seen with the T6’S mutation. Again, coupling was seen here, 
because all of these mutations seemed to aid in changing the gating equilibrium and thus 
 
Figure 5.7 Plot of log EC50 fold shifts with and without PNU-120596. Mutations that 
show no coupling ())G < 0.5 kcal/mol) form a linear line while those with values of  
))G > 0.5 kcal/mol lie off the relationship. Based on the double perturbation cycle 
analysis, this type of result is expected. This way graphically represents the fold shift data 
in this report and visually shows the non-additivity from the introduced mutations. 
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diminish the total effect PNU-120596 can exert on the system. M301A (adjacent to the 
putative PNU-120596 binding site) and M276L (on the M2 pore-lining helix) most likely 
contribute to structural rearrangements in the transmembrane region. In addition, the 
mutation L60 shows a large gain of function for acetylcholine alone, which suggests a 
possible re-structuring coupled to the agonist binding site. Thus, the allosteric 
propagation between acetylcholine and PNU-120596 is highly disrupted and could cause 
the PNU-120596 to become a weak agonist. 
Another surprising result seen here is that several residues previously implicated 
in PNU-120596 binding do not show functional coupling with respect to transmitting the 
effects of PNU-120596. Previously, the binding pocket had been proposed to lie in the 
transmembrane region and to interact with residues on the M1, M2, and M4 "-helices 
(22,31). Even though these residues were implicated in comprising the PNU-120596 
binding, they may not contribute to allosteric propagation in the protein – which is 
analogous to the residues critical for acetylcholine binding shown above. Residues 
adjacent to the pockets were implicated in the communication pathway: N75 lies on the 
#2 strand connected to loop 2; C241 & S245 lie on the M1 helix and F275 on the M2 
helix. Remarkably, both of these edges of the binding sites seem to be oriented for 
interaction with residues at the gating interface. The residues E195 (Loop 9), Y232 (M1), 
and N236 (M1) of one subunit are located in the vicinity of E67 (Loop 2), W156 (Loop 
7), and S287 (M2-3 Linker) of the adjacent subunit. This suggests the presence of a 
collection of residues in the gating interface region that communicates the allosteric 
potentiation between the extracellular and transmembrane regions (Figure 5.6). This 
interpretation is reinforced by the fact that five of these six residues (excluding W156) 
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show nearly "7 wild type response waveforms even when PNU-120596 is present 
(Table 5.4). The increase in decay current rates back to wild type waveforms even when 
PNU-120596 is present suggests that these residues are vital to propagation of the 
PNU-120596 allosteric properties. Even though the residue N193 is not included in this 
complex despite its proximity, a possible explanation for the effects previously seen by 
Barron et al. is that its physical location can be reorienting because the above-mentioned 
complex movements change the solvent exposure (17). 
PNU-120596 thus exerts positive allosteric modulation by binding in the 
transmembrane region, which stabilizes the gating interface and changes the gating 
equilibrium of the receptor, allowing for a lower concentration of the agonist to open the 
channel. Also, stabilizing this interaction prolongs channel activation, presumably by 
decelerating desensitization of the "7 receptor, which is the most rapidly desensitizing 
nAChR known (30). Naturally this suggests a global interaction involving a complex 
change in the stability of the wild type receptor after agonist binding. Here we have 
provided a quantitative analysis for identification of residues necessary for proper 
propagation of allosteric effects.  
 
5.5 Conclusions 
Nicotinic acetylcholine receptors (nAChRs) are critical contributors to neuronal 
communication, which also implicates them in vital normal brain processes as well as 
neural diseases. The "7 nAChR in particular has been implicated in Alzheimer’s disease; 
thus the molecular understanding of how compounds affect this receptor has attracted 
much interest !"#$"%&. Attempts to design small molecules that are specific to "7 have 
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yielded numerous agonists with some therapeutic success (40). As an alternative to 
selective agonist design, research towards the development and understanding of 
allosteric modulators – which have the potential to be more target specific and thus 
produce fewer side effects – has generated progress (32,41). In this study, the use of 
non-canonical amino acids allowed individual chemical interactions of the agonist 
binding to the protein to be probed in the presence of the "7-specific positive allosteric 
modulator PNU-120596. The conclusion from this analysis is that PNU-120596 does not 
alter the agonist binding pocket. To further probe the molecular basis of the properties of 
PNU-120596, conventional mutagenesis throughout the receptor was performed. Several 
gating interface residues as well as transmembrane residues were identified as vital for 
propagating PNU-120596 properties throughout the receptor. This network of residues 
links the agonist binding site to the PNU-120596 binding site and to the channel gate in 
the pore of the receptor, influencing the global stabilization of the gating equilibrium. 
 
5.6 Methods 
5.6.1 Residue Numbering and Protein Modeling 
 Residue numbering was based on the full-length protein containing the signaling 
sequence as found on the Ligand Gated Ion Channel Database 
(http://lenoverelab.org/LGICdb/LGICdb.php). The figures were generated using PyMOL 
and a homology model (generated via MODELLER) of the rat "7 receptor based on the 
GluCl crystal structure (PDB 3RHW) (42). 
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5.6.2 Molecular Biology  
The QuikChange protocol (Stratagene) was used for site-directed mutagenesis of 
the rat nAChR "7 subunit (pAMV vector). NotI was used to linearize the circular 
plasmid. The DNA was purified (Qiagen) and in vitro transcription of mRNA from the 
linearized DNA templates was performed using the T7 mMessage Machine kit (Ambion). 
The resulting mRNA was purified and isolated using Qiagen’s RNeasy RNA purification 
kit. The same linearization and mRNA synthesis protocols were used for the human Ric3 
(pAMV) accessory protein. 
For non-canonical amino acid incorporation, the amber (UAG) stop codon was 
used for all "7 subunit incorporation. The 74-nucleotide THG73 tRNA and 76-nucleotide 
THG73 tRNA were in vitro transcribed using the MEGAshortscript T7 (Ambion) kit and 
isolated using Chroma Spin DEPC-H2O columns (Clontech). Synthesized non-canonical 
amino acids coupled to the dinucleotide dCA were enzymatically ligated to the 
74-nucleotide tRNA as previously described (27,43).  
ND96 media was used for all experimental running/wash buffer (96 mM NaCl, 
1.8mM CaCl2, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES at pH 7.5). ND96+ media was 
used for oocyte storage media (2.5mM sodium pyruvate and 6.7mM theophylline). No 
gentamicin was added to the ND96+ storage media in order to avoid distorting ACh-
induced responses (44). 
 
5.6.3 Oocyte Preparation and Injection  
Xenopus laevis stage V and VI oocytes were harvested via standard protocols 
(43). For conventional mutagenesis, mRNA mixtures of "7 and Ric3 (45-49) were mixed 
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at a ratio of 1:1 by weight to a final concentration of 0.8 ng/nL. Each oocyte received a 
50 nL injection for a 40 ng total mRNA mass delivery. Oocytes were incubated at 18° C 
for 24-48 h. For non-canonical amino acid incorporation, mRNA mixtures of "7 and 
Ric3 were made in a 1:1 ratio to a final concentration of 1.6 ng/nL. These mRNA 
mixtures were then mixed in a 1:1 volume ratio with de-protected (photolysis) tRNA, and 
50 nL were injected into each oocyte. Oocytes were incubated at 18° C for 24 h. For 
non-canonical amino acids that showed no response after 24 h, the oocyte was subjected 
to a second injection and incubation following the aforementioned procedure. 
Read-through/reaminoacylation tests (76-nucleotide THG73 tRNA) were performed to 
confirm non-canonical amino acid incorporation (19)/ 
 
5.6.4 Chemical Preparation 
Acetylcholine Chloride (Sigma-Aldrich) was dissolved to 1 M stock solutions in 
ND96 buffer. PNU-120596 (Selleckchem) was dissolved in DMSO to 150 mM stock 
solutions. Further dilution was performed to make a 10 µM and 0.1% v/v DMSO solution 
for experimentation. 
 
5.6.5 Electrophysiology 
The two-electrode voltage clamp mode of an OpusXpress 6000A (Axon 
Instruments) was used. A holding potential of -60 mV and ND96 media for running 
buffer were used.  
For acetylcholine EC50 measurements, 2-fold and 2.5-fold acetylcholine 
concentration steps were applied over several orders of magnitude for dose-response 
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measurements. Drug applications consisted of applying 1 mL of solution over 8 s. Then 
the oocytes were washed with buffer for 3 min at a rate of 3 mL min-1 before the next 
application of drug. For the acetylcholine and PNU-120596 EC50 measurements, a similar 
protocol was used. PNU-120596 at a 10 µM concentration was pumped in at a rate of 
3 mL min-1 for 30 s (1.5 mL total volume per oocyte) prior to the co-application of 
acetylcholine and 10 µM PNU-120596. The co-application dose was 1 mL of solution 
over 15 s followed by an additional 15 s pause to allow each response to reach its 
maximum value. Then the oocytes were washed with buffer for 5 min at a rate of 3 mL 
min-1 before the next co-application of drug. Again, 2-fold and 2.5-fold acetylcholine 
concentration steps were used over several orders of magnitude. 
Data were sampled at 50 Hz and then low-passed filtered at 5 Hz. Data were 
normalized on a per cell basis, response was averaged on a per concentration basis, and 
then fit to a single Hill term to generate EC50 and Hill coefficient (nH) values. Error bars 
represent standard error of the mean (SEM) values. 
 
5.7 Acknowledgments 
We thank Matt Rienzo and Noah Duffy for their work in making the dCA-coupled 
fluorinated-OMe-Tyrosines and tRNA, and Emily Blythe for developing the "7 
homology model. Support for this work came from the NIH (NS 34407).  
  
%%+!
5.8 References 
 
1. Lemoine, D., Jiang, R., Taly, A., Chataigneau, T., Specht, A., and Grutter, T. 
(2012) Ligand-gated ion channels: new insights into neurological disorders and 
ligand recognition. Chemical Reviews 112, 6285-6318 
2. Unwin, N. (2005) Refined structure of the nicotinic acetylcholine receptor at 4Å 
resolution. Journal of Molecular Biology 346, 967-989 
3. Dougherty, D. A. (2008) Cys-Loop Neuroreceptors: Structure to the Rescue? 
Chemical Reviews 108, 1642-1653 
4. Millar, N. S., and Gotti, C. (2009) Diversity of vertebrate nicotinic acetylcholine 
receptors. Neuropharmacology 56, 237-246 
5. Monod, J., Wyman, J., and Changeux, J. P. (1965) On the nature of allosteric 
transitions: A plausible model. J. Mol. Biol. 12, 88-118 
6. Edelstein, S. J., and Changeux, J. P. (1998) Allosteric transitions of the 
acetylcholine receptor. Adv Protein Chem 51, 121-184 
7. Karlin, A. (1967) On the application of "a plausible model" of allosteric proteins 
to the receptor for acetylcholine. Journal of Theoretical Biology 16, 306-320 
8. Heidmann, T., and Changeux, J. P. (1986) Characterization of the transient 
agonist-triggered state of the acetylcholine receptor rapidly labeled by the 
noncompetitive blocker [3H]chlorpromazine: additional evidence for the open 
channel conformation. Biochemistry 25, 6109-6113 
9. Katz, B., and Thesleff, S. (1957) A study of 'desensitization' produced by 
acetylcholine at the motor end-plate. J Physiol (Lond.) 138, 63-80 
10. Gronlien, J. H., Hakerud, M., Ween, H., Thorin-Hagene, K., Briggs, C. A., 
Gopalakrishnan, M., and Malysz, J. (2007) Distinct profiles of "7 nAChR 
positive allosteric modulation revealed by structurally diverse chemotypes. 
Molecular Pharmacology 72, 715-724 
11. Faghih, R., Gopalakrishnan, M., and Briggs, C. A. (2008) Allosteric Modulators 
of the "7 Nicotinic Acetylcholine Receptor. Journal of Medicinal Chemistry 51, 
701-712 
12. Bertrand, D., and Gopalakrishnan, M. (2007) Allosteric modulation of nicotinic 
acetylcholine receptors. Biochemical Pharmacology 74, 1155-1163 
13. Hurst, R. S., Hajos, M., Raggenbass, M., Wall, T. M., Higdon, N. R., Lawson, J. 
A., Rutherford-Root, K. L., Berkenpas, M. B., Hoffmann, W. E., Piotrowski, D. 
W., Groppi, V. E., Allaman, G., Ogier, R., Bertrand, S., Bertrand, D., and Arneric, 
S. P. (2005) A novel positive allosteric modulator of the "7 neuronal nicotinic 
acetylcholine receptor: in vitro and in vivo characterization. The Journal of 
Neuroscience: the Official Journal of the Society for Neuroscience 25, 4396-4405 
14. Szabo, A. K., Pesti, K., Mike, A., and Vizi, E. S. (2014) Mode of action of the 
positive modulator PNU-120596 on "7 nicotinic acetylcholine receptors. 
Neuropharmacology 81, 42-54 
15. Williams, D. K., Wang, J., and Papke, R. L. (2011) Investigation of the molecular 
mechanism of the "7 nicotinic acetylcholine receptor positive allosteric modulator 
PNU-120596 provides evidence for two distinct desensitized states. Molecular 
Pharmacology 80, 1013-1032 
%%,!
16. Pa'czy(ska, M. M., Jindrichova, M., Gibb, A. J., and Millar, N. S. (2012) 
Activation of "7 Nicotinic Receptors by Orthosteric and Allosteric Agonists: 
Influence on Single-Channel Kinetics and Conductance. Molecular 
Pharmacology 82, 910-917 
17. Barron, S. C., McLaughlin, J. T., See, J. A., Richards, V. L., and Rosenberg, R. L. 
(2009) An allosteric modulator of "7 nicotinic receptors, N-(5-Chloro-2,4-
dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea (PNU-120596), causes 
conformational changes in the extracellular ligand binding domain similar to 
those caused by acetylcholine. Molecular Pharmacology 76, 253-263 
18. Dougherty, D. A., and Van Arnam, E. B. (2014) In vivo incorporation of non-
canonical amino acids by using the chemical aminoacylation strategy: a broadly 
applicable mechanistic tool. Chembiochem : a European Journal of Chemical 
Biology 15, 1710-1720 
19. Van Arnam, E. B., Blythe, E. E., Lester, H. A., and Dougherty, D. A. (2013) An 
unusual pattern of ligand-receptor interactions for the "7 nicotinic acetylcholine 
receptor, with implications for the binding of varenicline. Molecular 
Pharmacology 84, 201-207 
20. Tavares Xda, S., Blum, A. P., Nakamura, D. T., Puskar, N. L., Shanata, J. A., 
Lester, H. A., and Dougherty, D. A. (2012) Variations in binding among several 
agonists at two stoichiometries of the neuronal, "4#2 nicotinic receptor. Journal 
of the American Chemical Society 134, 11474-11480 
21. Bertrand, D., Bertrand, S., Cassar, S., Gubbins, E., Li, J., and Gopalakrishnan, M. 
(2008) Positive allosteric modulation of the "7 nicotinic acetylcholine receptor: 
ligand interactions with distinct binding sites and evidence for a prominent role of 
the M2-M3 segment. Molecular Pharmacology 74, 1407-1416 
22. Young, G. T., Zwart, R., Walker, A. S., Sher, E., and Millar, N. S. (2008) 
Potentiation of "7 nicotinic acetylcholine receptors via an allosteric 
transmembrane site. Proceedings of the National Academy of Sciences of the 
United States of America 105, 14686-14691 
23. Gleitsman, K. R., Shanata, J. A., Frazier, S. J., Lester, H. A., and Dougherty, D. 
A. (2009) Long-range coupling in an allosteric receptor revealed by mutant cycle 
analysis. Biophysical Journal 96, 3168-3178 
24. Daeffler, K. N., Lester, H. A., and Dougherty, D. A. (2012) Functionally 
important aromatic-aromatic and sulfur-' interactions in the D2 dopamine 
receptor. Journal of the American Chemical Society 134, 14890-14896 
25. Miles, T. F., Bower, K. S., Lester, H. A., and Dougherty, D. A. (2012) A coupled 
array of noncovalent interactions impacts the function of the 5-HT3A serotonin 
receptor in an agonist-specific way. ACS Chemical Neuroscience 3, 753-760 
26. Lummis, S. C., Beene, D. L., Lee, L. W., Lester, H. A., Broadhurst, R. W., and 
Dougherty, D. A. (2005) Cis-trans isomerization at a proline opens the pore of a 
neurotransmitter-gated ion channel. Nature 438, 248-252 
27. Xiu, X., Puskar, N. L., Shanata, J. A., Lester, H. A., and Dougherty, D. A. (2009) 
Nicotine binding to brain receptors requires a strong cation-' interaction. Nature 
458, 534-537 
%%-!
28. Puskar, N. L., Xiu, X., Lester, H. A., and Dougherty, D. A. (2011) Two neuronal 
nicotinic acetylcholine receptors, "4#4 and "7, show differential agonist binding 
modes. The Journal of Biological Chemistry 286, 14618-14627 
29. Papke, R. L., Horenstein, N. A., Kulkarni, A. R., Stokes, C., Corrie, L. W., 
Maeng, C. Y., and Thakur, G. A. (2014) The activity of GAT107, an allosteric 
activator and positive modulator of "7 nicotinic acetylcholine receptors (nAChR), 
is regulated by aromatic amino acids that span the subunit interface. The Journal 
of Biological Chemistry 289, 4515-4531 
30. Zhang, J., Xue, F., Whiteaker, P., Li, C., Wu, W., Shen, B., Huang, Y., Lukas, R. 
J., and Chang, Y. (2011) Desensitization of "7 nicotinic receptor is governed by 
coupling strength relative to gate tightness. The Journal of Biological Chemistry 
286, 25331-25340 
31. Collins, T., Young, G. T., and Millar, N. S. (2011) Competitive binding at a 
nicotinic receptor transmembrane site of two "7-selective positive allosteric 
modulators with differing effects on agonist-evoked desensitization. 
Neuropharmacology 61, 1306-1313 
32. Williams, D. K., Wang, J., and Papke, R. L. (2011) Positive allosteric modulators 
as an approach to nicotinic acetylcholine receptor-targeted therapeutics: 
advantages and limitations. Biochemical Pharmacology 82, 915-930 
33. Hanek, A. P., Lester, H. A., and Dougherty, D. A. (2008) A Stereochemical Test 
of a Proposed Structural Feature of the Nicotinic Acetylcholine Receptor. Journal 
of the American Chemical Society 130, 13216-13218 
34. Tillman, T. S., Seyoum, E., Mowrey, D. D., Xu, Y., and Tang, P. (2014) ELIC- 
"7 Nicotinic acetylcholine receptor ("7nAChR) chimeras reveal a prominent role 
of the extracellular-transmembrane domain interface in allosteric modulation. The 
Journal of Biological Chemistry 289, 13851-13857 
35. Young, J. W., and Geyer, M. A. (2013) Evaluating the role of the "7 nicotinic 
acetylcholine receptor in the pathophysiology and treatment of schizophrenia. 
Biochemical Pharmacology 86, 1122-1132 
36. Pandya, A. A., and Yakel, J. L. (2013) Effects of neuronal nicotinic acetylcholine 
receptor allosteric modulators in animal behavior studies. Biochemical 
Pharmacology 86, 1054-1062 
37. Narla, S., Klejbor, I., Birkaya, B., Lee, Y. W., Morys, J., Stachowiak, E. K., 
Terranova, C., Bencherif, M., and Stachowiak, M. K. (2013) "7 nicotinic receptor 
agonist reactivates neurogenesis in adult brain. Biochemical Pharmacology 86, 
1099-1104 
38. Tong, M., Arora, K., White, M. M., and Nichols, R. A. (2011) Role of key 
aromatic residues in the ligand-binding domain of "7 nicotinic receptors in the 
agonist action of #-amyloid. The Journal of Biological Chemistry 286, 34373-
34381 
39. Parri, H. R., Hernandez, C. M., and Dineley, K. T. (2011) Research update: "7 
nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochemical 
Pharmacology 82, 931-942 
40. Horenstein, N. A., Leonik, F. M., and Papke, R. L. (2008) Multiple 
pharmacophores for the selective activation of nicotinic "7-type acetylcholine 
receptors. Molecular Pharmacology 74, 1496-1511 
%&.!
41. Christopoulos, A. (2002) Allosteric binding sites on cell-surface receptors: novel 
targets for drug discovery. Nature Reviews. Drug Discovery 1, 198-210 
42. Hibbs, R. E., and Gouaux, E. (2011) Principles of activation and permeation in an 
anion-selective Cys-loop receptor. Nature 474, 54-60 
43. Nowak, M., Gallivan, J. P., Silverman, S., Labarca, C. G., Dougherty, D. A., and 
Lester, H. A. (1998) In Vivo Incorporation of Unnatural Amino Acids into Ion 
Channels in Xenopus Oocyte Expression System. Methods Enzymol 293, 504-529 
44. Amici, M., Eusebi, F., and Miledi, R. (2005) Effects of the antibiotic gentamicin 
on nicotinic acetylcholine receptors. Neuropharmacology 49, 627-637 
45. Ben-Ami, H. C., Yassin, L., Farah, H., Michaeli, A., Eshel, M., and Treinin, M. 
(2005) RIC-3 affects properties and quantity of nicotinic acetylcholine receptors 
via a mechanism that does not require the coiled-coil domains. The Journal of 
Biological Chemistry 280, 28053-28060 
46. Castillo, M., Mulet, J., Gutierrez, L. M., Ortiz, J. A., Castelan, F., Gerber, S., 
Sala, S., Sala, F., and Criado, M. (2005) Dual role of the RIC-3 protein in 
trafficking of serotonin and nicotinic acetylcholine receptors. The Journal of 
Biological Chemistry 280, 27062-27068 
47. Cheng, A., McDonald, N. A., and Connolly, C. N. (2005) Cell surface expression 
of 5-hydroxytryptamine type 3 receptors is promoted by RIC-3. The Journal of 
Biological Chemistry 280, 22502-22507 
48. Halevi, S., McKay, J., Palfreyman, M., Yassin, L., Eshel, M., Jorgensen, E., and 
Treinin, M. (2002) The C. elegans ric-3 gene is required for maturation of 
nicotinic acetylcholine receptors. EMBO J 21, 1012-1020 
49. Williams, M. E., Burton, B., Urrutia, A., Shcherbatko, A., Chavez-Noriega, L. E., 
Cohen, C. J., and Aiyar, J. (2005) Ric-3 promotes functional expression of the 
nicotinic acetylcholine receptor "7 subunit in mammalian cells. The Journal of 
Biological Chemistry 280, 1257-1263 
 
  
%&%!
 
 
Appendix 1 
 
 
Autosomal Dominant Nocturnal Frontal Lobe Epilepsy Mutation Suppresses 
Low-Sensitivity (a4)3("2)2 Nicotinic Acetylcholine Receptor Expression* 
 
 
*The work described in this section was done in collaboration with Dr. Weston Nichols, 
Dr. Brandon Henderson, Caroline Yu, Dr. Chris Richards, and Dr. Bruce Cohen. 
 
A1.1 Abstract 
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is linked to 
mutations in "2, "4, and #2 nicotinic acetylcholine receptor (nAChR) subunits (1), as 
well as in a sodium-gated potassium channel (2). ADNFLE results in brief nocturnal 
seizures that occur mainly during slow-wave sleep. A number of ADNFLE nAChR 
mutations increase the sensitivity of "4#2 nAChRs to the endogenous agonist ACh and 
reduce allosteric Ca2+ potentiation (1,3). One ADNFLE mutation, V287L, is located in 
the pore-lining region of the nAChR #2 subunit (4,5). Previous studies have shown that 
agonist sensitivity, desensitization, single-channel conductance, and allosteric Ca2+ 
potentiation of "4#2 nAChRs change when this mutation is introduced to the 
receptor (4,5). The "4#2 receptor can assemble into several functional receptors with 
different stoichiometries, two of which are the high sensitivity ("4)2(#2)3 and low 
sensitivity ("4)3(#2)2 receptors (6,7). These two stoichiometries have been shown to be 
expressed and functional in native neuronal environments (8). In addition, the accessory 
subunit "5 can co-assemble with "4#2 subunits to form "5"4#2 nAChRs (9). 
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The effects of ADNFLE mutations on "4#2 subunit stoichiometry are vague (10). 
The goal of this collaboration was to use a combination of electrophysiological and 
fluorescent imaging techniques to resolve these ambiguities. The functional effects of 
 #2 V287L were measured via dose-response relationships of "4#2 and "5"4#2 nAChRs 
expressed in oocytes using two-electrode voltage clamp electrophysiology. Total internal 
reflection fluorescence (TIRF) microscopy using superecliptic pHluorin (SEP)-labeled 
"5, "4, #2, and #2 V287L nAChR subunits in HEK293 cells were used to measure 
surface expression of the different receptors. The results from these studies show that 
#2 V287L provides a gain-of-function to the ("4)2(#2)3 and ("4)3(#2)2 receptors, and 
suppresses ("4)3(#2)2 expression. In addition, #2 V287L increases "5"4#2 surface 
expression but does not affect functional responses to acetylcholine (ACh). 
Appendix 1 focuses on the interpretation of the oocyte experimental results I 
obtained for this collaboration. 
 
A1.2 Results and Discussion 
To determine whether ("4)3(#2)2 receptor suppression was inherent to the 
#2 V287L mutation, oocytes were injected with either "4#2  or "4#2 V287L mRNAs in 
a 1:1 or 10:1 "4:#2 ratio, and ACh EC50 measurements were obtained. Xenopus laevis 
oocytes can be biased in receptor expression by varying ratios of injected mRNAs. Equal 
amounts of "4 and #2 mRNA yields a mixture of ("4)2(#2)3 and ("4)3(#2)2 receptors, 
while an excess of "4 mRNA favors ("4)3(#2)2 receptor formation and an excess of #2 
favors ("4)2(#2)3 formation (6,7).   
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Injecting "4:#2 wild type (WT) mRNAs in a 1:1 ratio produced a biphasic ACh 
EC50 curve (Figure A1.1).  Data fitting yielded EC50 values for the two components 
differing by more than tenfold, with ("4)2(#2)3 receptors accounting for 65 ± 2% of the 
maximum WT response (Table A1.1).  In contrast, injecting "4:#2 V287L mRNAs in a 
1:1 ratio produced a monophasic ACh EC50 curve of high sensitivity (Figure A1.1), 
which suggests ("4)3(#2)2 receptor suppression from inclusion of the #2V287L mutation. 
The EC50 of the ("4)2(#2 V287L)3 mutant receptor shows a six-fold gain-of-function 
compared to ("4)2(#2)3 receptors (Table A1.1).  Thus, the #2 V287L mutation increased 
the sensitivity of ("4)2(#2)3 receptors while appearing to suppress the expression of 
("4)3(#2)2 receptors. 
Injecting "4:#2 mRNAs in a 10:1 ratio shifted the WT ACh EC50 curve rightward, 
indicating a more enriched ("4)3(#2)2 population (Figure A1.1). To estimate the 
percentage of the high sensitivity component, a biphasic ACh EC50 curve was fit after 
constraining the ("4)2(#2)3 contribution of the two components to the values obtained 
from fitting the "4:#2 1:1 data above (Table A1.1).  The percent of ("4)2(#2)3 receptors 
in the population was 7 ± 4% and that of ("4)3(#2)2 receptors was 93 ± 4 % 
(Table A1.1).  Thus, the WT 10:1 ACh EC50 curve relation was nearly monophasic, 
suggesting an almost complete suppression of ("4)2(#2)3 expression.   
Again a similar suppression and gain-of-function observation is seen when 
introducing the #2 V287L mutation. The 10:1 ratio of "4:#2 V287L mRNAs produced a 
notably biphasic ACh EC50 curve (Figure A1.1). Fitting the biphasic curve in a similar 
manner to the WT case by constraining the value for the ("4)2(#2 V287L)3 contribution, 
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the ("4)2(#2 V287L)3 receptors accounted for 23 ± 3% of the maximum response, and 
the ("4)3(#2 V287L)2 receptors for 77 ± 3% (Table 1).  The percentage of 
("4)2(#2 V287L)3 receptors for the 10:1 injection ratio was significantly larger than the 
corresponding value for the WT (Table A1.1). The #2 V287L mutation also reduced the 
EC50 of the ("4)3(#2 V287L)2 receptors by a factor of five (Table A1.1).  In summary, 
the #2 V287L mutation favors formation of the ("4)2(#2)3 stoichiometry, and it produces 
gain-of-function for ACh responses for both the ("4)2(#2 V287L)3 and ("4)3(#2 V287L)2 
receptors by similar factors.  
Since the #2V287L mutation had significant effects in sensitivity and 
stoichiometry of the "4#2 receptors, "5"4#2 receptors were also investigated for 
functional and assembly changes. Again, ratio biasing is used to generate enriched 
populations of the "5"4#2 receptors. Oocytes were injected with "5:"4:#2 or 
"5:"4:#2 V287L mRNAs, using a large excess of "5 ("5:"4:#2 ratio of 10:1:1) to favor 
"5:"4:#2 assembly (Figure A1.2).  The WT and #2 V287L ACh EC50 curves were 
monophasic and essentially identical to one another (Figure A1.2, Table A1.1). 
Surprisingly, the #2 V287L mutation did not alter the EC50 of "5"4#2 nAChRs. These 
results suggest that #2 V287L does not affect the ACh sensitivity of "5* nAChRs despite 
the large effects seen in "4#2 nAChRs. 
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Figure A1.1 ACh EC50 curves for "4#2 and "4#2 V287L nAChRs expressed in Xenopus 
oocytes using 1:1 (A-B, E) and 10:1 "4:#2 mRNA injection ratios (C-D, F). The traces 
are voltage-clamped ACh responses of oocytes injected with (A) "4#2 or 
(B) "4#2 V287L in a 1:1 "4:#2 stoichiometric ratio (w/w). The ACh concentrations 
(in µM) are listed to the left of, or below, the traces. The bars above the traces show the 
timing and duration of the ACh application. For clarity, only a subset of the 18 responses 
recorded from each oocyte is shown. Voltage-clamped traces of (C) "4#2 and 
(D) "4#2 V287L responses using a 10:1 "4:#2 injection ratio. (E-F) Normalized ACh 
EC50 curves for the "4#2 (filled circles) and "4#2 V287L nAChRs (open circles) using 
(E) 1:1  and (F) 10:1  "4:#2 injection ratios. Lines are fit to one or two Hill terms to 
generate EC50 and Hill coefficient (nH) values. 
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TABLE A1.1 
Receptor 
":# mRNA 
Injection Ratio 
Component % of Total EC50 (µM) 
"4#2 1:1 HS 65 ± 2 (8) 0.67 ± 0.08 (8) 
  LS 35 ± 2 (8) 190 ± 60 (8) 
"4#2 V287L 1:1 HS 100 0.11 ± 0.01 (8)*** 
"4#2 10:1 HS 7 ± 4 (17) 0.67 (fixed) 
  LS 93 ± 4 (17) 190 (fixed) 
"4#2 V287L 10:1 HS 23 ± 3 (7)** 0.11 (fixed) 
  LS 77 ± 3 (7) 36 ± 7 (7)* 
"5"4#2 10:1:1 HS 100 0.26 ± 0.04 (4) 
"5"4#2 V287L 10:1:1 HS 100 0.32 ± 0.01 (8) 
Fitted parameters for the ACh concentration-response relations of !4"2, !4"2 V287L, !5!4"2, and 
!5!4"2 V287L nAChRs expressed in oocytes. Values are mean ± S.E. (number of oocytes). HS and LS 
denote (!4)2("2)3 and (!4)2("2)3 components of the concentration-response relations, respectively. For 
single-component concentration-response relations the percent of total (% of total) was fixed at 100%. 
Parameters constrained to a particular value are denoted as (fixed). Mutant values that differ significantly 
from WT (!4"2) at the 0.05. 0.01, and 0.001 levels are marked (*), (**), and (***), respectively. 
 
 
Figure A2.2 ACh EC50 curves for "5"4#2 and "5"4#2 V287L nAChRs expressed in 
Xenopus oocytes using a large excess of "5 mRNA ensure that "5-containing ("5*) 
nAChRs were the predominant subtype ("5:"4:#2 mRNA injection ratio of 
10:1:1 w/w/w). Voltage-clamped ACh responses of oocytes injected with (A) "5"4#2 or 
(B) "5"4#2 V287L. (C) Normalized ACh EC50 curves for the WT "5"4#2 (filled 
circles), and "5"4#2 V287L (open circles). 
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A1.3 Methods 
A1.3.1 Molecular Biology  
Mouse nAChR "5, "4, and #2 subunits were subcloned into pGEMhe, and the 
QuikChange protocol (Stratagene) was used for site-directed mutagenesis. The resulting 
plasmids of "4 and #2 DNA were linearized using the SbfI restriction enzyme. Plasmids 
of "5 DNA were linearized using the SphI restriction enzyme. The linearized DNA 
template was purified (Qiagen) and used for mRNA synthesis via the T7 mMessage 
Machine kit (Ambion) run-off transcription. Qiagen’s RNeasy RNA purification kit was 
used to purify the resulting mRNA. 
 
A1.3.2 Oocyte Injection 
Standard protocols were performed to harvest Xenopus laevis stage V and VI 
oocytes (11). The "5, "4, and #2 mRNA were mixed with a 10:1:1 ratio by mass to 
produced a 0.8 ng/nL concentration. 50 nL were injected into the oocytes delivering 
40 ng of total mRNA. The "4 and #2 mRNA were mixed with a mass ratio of 1:1 to 
produce a 0.13 ng/nL concentration and a mass ratio of 10:1 to produce a 0.42 ng/nL 
concentration. 50 nL were injected to deliver 6.7 ng and 21 ng of total mRNA, 
respectively. Oocytes were stored in ND96+ medium and incubated at 18°C for 24-96 h 
post injection.  
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A1.3.3 Electrophysiology  
Acetylcholine chloride was purchased from Sigma-Aldrich and dissolved to a 1 M 
stock solution in ND96 Ca2+ free buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 
5 mM HEPES at pH 7.5).  
The OpusXpress 6000A (Axon Instruments) two electrode voltage clamp mode 
was used for electrophysiological recordings. For all recordings, the holding potential 
was –60 mV and the ND96 Ca2+ free solution was used as the running buffer.  All 
measurements involved 1 mL of drug solution applied over 15 s followed by a 2 min 
buffer wash. Dose-response curves involved a three concentration series (approximately 
three-fold between each) spanning several orders of magnitude, which totaled eight to 
eighteen doses. Data were low-pass filtered at 5 Hz before determining the current 
response for each dose application.  
Each cell was individually normalized to its own max response. These results 
were then averaged and fit to one or two Hill terms to generate EC50 and Hill coefficient 
(nH) values. Error is represented by standard error of the mean (SEM). 
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Appendix 2 
 
 
Ligand-Gated Ion Channel Screen of Physostigmine Derivatives 
for Allosteric Modulation and Receptor Agonism* 
 
 
*The work described in this section was done in collaboration with Dr. Kristina Daeffler, 
Dr. Lindsey Repka, and Alex Maolanon. 
 
A2.1 Abstract 
 The goal of this collaboration was to screen synthetic, drug-like compounds for 
activation, potentiation, or inhibition of several ligand-gated ion channels (LGICs). 
Dr. Lindsey Repka and Alex Maolanon of the Reisman group developed and utilized a 
novel synthetic scheme for organic compounds that are structurally similar to 
physostigmine, which is a clinically used acetylcholinesterase inhibitor and positive 
allosteric modulator (PAM) of nicotinic acetylcholine receptors (nAChRs) (1,2). The 
Reisman group provided five compounds that were screened with the help of Dr. Kristina 
Daeffler against seven LGICs: the "7 (T6’S), ("4L9’A)3(#2)2, and muscle-type nAChRs 
and the 5-HT3A, GABAA("#$), glycine, and GluR2 receptors. Most compounds were 
either channel blockers with varying levels of potencies for nicotinic acetylcholine 
receptors or non-interacting for other channels probed. However, compound AMAO-1-86 
showed weak partial agonism and demonstrated PAM properties at the GABAA("#$) 
receptor. Agonism was eliminated and PAM properties diminished when tested against 
the GABAA("#) receptor, which suggests potential binding at the "-$ interface, like 
%'%!
benzodiazepines. Further studies are needed to confirm the results from the GABAA("#) 
study and to identify the actual binding site of AMAO-1-86. 
 
 
Figure A2.1 Chemical structures of physostigmine and the synthetic derivatives provided 
by Dr. Lindsey Repka and Alex Maolanon. 
 
 
A2.2 Results and Discussion 
A2.2.1 Screening Compounds for Functional Properties at Various LGICs 
 Five derivatives (Figure A2.1) based on the core ring structure of physostigmine 
were tested across the seven LGICs. The PAM protocol from Chapter 4 was used to 
study these molecules. This included three native agonist EC50 doses, one 60 s incubation 
of the compound with an immediate co-application of an EC50 dose, and two native 
agonist EC50 doses (Figure A2.2). Since the goal was to screen for “hit” compounds, the 
concentration of molecule being tested was 20-40 µM. This protocol allows for 
identification of activation, inhibition, and/or positive allosteric modulation of the 
receptor. All percent increases or decreases are relative to the EC50 response of the 
receptor. These values may change based on higher or lower doses of agonist or ligand 
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tested; however these concentrations provide an adequate range in order to observe 
increasing (PAM) or decreasing (inhibition) receptor response. 
 Nearly all the compounds studied showed either no effect or inhibition of receptor 
response (Table A2.1). The one exception was AMAO-1-86, which was a weak partial 
agonist (~10% channel activation at 40 µM) and a PAM (~50% increase of the EC50 
response) for the GABAA("#$) receptor (Table A2.1 and Figure A2.2). Increasing the 
concentration of AMAO-1-86 showed an increase in receptor response, indicating that it 
acts in a dose-dependent manner. However, available quantity and solubility issues 
hampered efforts to obtain a full EC50 curve due to lack of potency (possibly high µM 
EC50). Removal of the $ subunit generates the GABAA("#) receptor, which showed 
elimination of agonist activity and marked reduction of positive allosteric modulation 
(~15% increase of the EC50 response). This suggests interactions with the "-$ interface 
for AMAO-1-86 or at least a strong role for the $ subunit in AMAO-1-86 receptor 
modulation. Further studies are needed for replication of the GABAA("#) experiment and 
 
Figure A2.2 Example of protocol used for screening the compounds against LGICs. The 
black bars represent native agonist EC50 doses. The blue bar represents the compound 
being tested. The novel result of AMAO-1-86 being a weak partial agonist and PAM of 
GABAA("#$) is shown in these traces.  
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further mutational screening will be needed to identify the binding site of AMAO-1-86. 
The first place to try would involve the "1 H129R mutation which has been shown to 
eliminate benzodiazepine modulation of the GABAA("#$) (3). Other studies have shown 
differential residue movements on activation when benzodiazepines are co-applied with 
receptor agonists (4,5).  
 For the rest of the receptors and compounds, co-application resulted in either no 
effect or inhibition. GluR and glycine receptors were relatively inert to the ligands 
applied here. 5-HT3A exhibited a similar trend except ~25% drop in signal for the 
AMAO-1-71 compound. The largest inhibition results were seen for the nAChRs: 
muscle-type, ("4L9’A)3(#2)2, and "7 (T6’S) (Table A2.1). The "7 (T6’S) receptor 
consistently had the highest inhibition values. The muscle-type and ("4L9’A)3(#2)2 
receptors had modest inhibition across all the compounds except for AMAO-1-98, which 
only inhibited the "7 (T6’S) receptor. This is not surprising due to the promiscuity in 
compound activation, inhibition, and modulation for "7 nAChRs (6,7). No other positive 
modulation was observed for the remaining receptors screened. All derivatives had 
different levels of inhibition, indicating some receptor specificity. To better understand 
Table A2.1 
Percent change in EC50 response when co-applied with indicated ligand. Negative values represent signal 
decreases while positive values represent signal increases. 
Receptor 
Percent (%) change in current with co-application of EC50 dose and 20-40 µM of Compound 
AMAO-1 AMAO-1-71 AMAO-1-86 AMAO-1-98 AMAO-1-100 
Muscle (9’) –21 ± 1 –29 ± 3 –53 ± 3 –7 ± 3 –81 ± 6 
("4L9’A)3(#2)2 –28 ± 2 –47 ± 4 –29 ± 6 –11 ± 2 –44 ± 2 
"7 (T6’S) –62 ± 4 –68 ± 7 –92 ± 4 –57 ± 10 –96 ± 3 
5-HT3A – 3 ± 2 –23 ± 4 –3 ± 5 3 ± 12 –11 ± 8 
GABAA("#$) –27 ± 4 –27 ± 11 52 ± 10 –27 ± 21 10 ± 5 
GABAA("#)   16 ± 2   
GluR2 –6 ± 1 0 ± 2 –9 ± 6 –11 ± 5 –12 ± 5 
Glycine –6 –9 ± 9 3 ± 7 18 ± 10 –16 ± 6 
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the mode of inhibition, further studies were performed on AMAO-1 because it was the 
most water-soluble and most abundant analog synthesized. 
 
A2.2.1 Physostigmine Analog Inhibition Characterization 
 Receptor inhibition can occur in several different modes: channel block, 
antagonism, and negative allosteric modulation (NAM). IC50 curves and voltage-jump 
experiments were performed to delineate how AMAO-1 was inhibiting the nAChRs. 
Figure A2.3 shows the IC50 curves for "7 (T6’S) and ("4L9’A)3(#2)2 receptors. Lower 
doses of AMAO-1 showed a large variability in inhibition, suggesting a slow on-rate of 
the compound. The "7 (T6’S) and ("4L9’A)3(#2)2 receptor IC50 values were 5 µM and 8 
µM and Hill coefficients were -0.8 and -1.2, respectively. The Hill coefficient of near 1 
suggests that only one molecule is needed to inhibit the channel. This seems to rule out 
AMAO-1 as an antagonist since there are five binding sites for the "7 (T6’S) nAChR and 
 
Figure A2.3 IC50 curves of AMAO-1 at (A) "7 (T6’S) and (B) ("4L9’A)3(#2)2. m2 and 
m3 represent the IC50 and Hill coefficient, respectively. 
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three sites for the ("4L9’A)3(#2)2 receptor. This still leaves the channel blocker and 
NAM profile. Hoever, the NAM profile is unlikely since there tends to be multiple 
binding locations for allosteric modulators, which is similar to agonist binding sites. 
 Voltage-jump experiments were performed on ("4L9’A)3(#2)2 receptors to test if 
AMAO-1 is acting through a channel blocker mechanism. Comparison of 
positive-to-negative and negative-to-positive voltage-jumps can indicate if a compound is 
acting as a channel blocker and this has been previously done for characterization of 
hexamethonium at "4#2 nAChRs (8). AMAO-1 did not exhibit similar 
voltage-dependence as hexamethonium (Figure A2.4). This is probably due to AMAO-1 
having a net neutral charge and hexamethonium being positively charged, which is 
influenced more by relative cell holding potentials. It is more likely that AMAO-1 is a 
channel blocker and further studies on the other charged derivatives would most likely 
resemble the voltage-jump results of hexamethonium.  
 
 
Figure A2.4 Example of voltage jump results of a single cell expressing ("4L9’A)3(#2)2. 
Minor changes are seen when varying the voltage from negative-to-positive (left) and 
positive-to-negative (right) when AMAO-1 is present. 
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A2.3 Conclusions 
 The physostigmine analogs exhibited here show a variety of activities among a 
series of LGICs. For the most part, these compounds behave as inhibitors of nAChRs and 
generally are inactive at other Cys-loop receptors, with minor exceptions (GABAA and 
one instance at 5-HT3A). Due to the low Hill coefficients and low sensitivity (mid-µM 
range) for inhibition of nAChRs, they most likely are acting via a channel blocker 
mechanism. Although the voltage-jump experiments performed here do not corroborate 
this observation, the compound tested was net neutral and differs from the original 
comparison (positively charged channel blocker). Testing a charged analog would 
probably resemble a voltage-jump experiment for hexamethonium channel blocking.  
 The more exciting result involved the partial activation and positive allosteric 
modulation of GABAA("#$) with AMAO-1-86. The effects were eliminated with 
introduction of small chemical changes: alcohol to amine (AMAO-1-100), tertiary to 
secondary amine (AMAO-1-98), and addition of a carboxyl group (AMAO-1). In 
addition, preliminary results show elimination of the agonist activity and reduction of the 
allosteric modulation when the $ subunit is removed to form GABAA("#$). These data 
suggests a distinct binding environment for the compound and point to a binding region 
possibly involving the "-$ subunit interface. Further investigation involving receptor 
mutation screening as well as synthesis of other derivatives of AMAO-1-86 would prove 
useful in identifying the binding region of a structurally novel PAM for GABAA("#$) 
receptors 
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A2.4 Methods 
 An adapted PAM protocol outlined in Chapter 4 was used for the LGIC screen 
experiments. First, three EC50 doses (of which the first was ignored) of the native agonist 
were applied with a 2-5 min washout in between applications. All cell responses were 
normalized to the largest response pre-ligand exposure. The next application in the series 
involved a 60 s pre-incubation of 20-40 µM of the ligand followed immediately by a co-
application of the ligand and native agonist EC50 dose. This tested for direct receptor 
activation (agonist with the pre-incubation dose) and allosteric modulation/inhibition 
(co-application dose). Finally, two EC50 doses similar to the first three were performed to 
show the ligand’s ability to be washed out and have receptor response returned to the 
baseline agonist-only applications. Averaging current responses from doses two and three 
(EC50 agonist response only) and subtracting from the co-application dose (ligand and 
EC50 agonist) gave the calculated change in response. Multiplying this value by 100% 
gave the percent inhibition/activation of the ligand. Agonist EC50 values for each receptor 
studied were: 100 µM ACh ("7 T6’S), 1.2 µM (muscle-type L9’A), 0.05 µM 
(("4L9’A)3(#2)2), 3 µM 5-HT (5-HT3A receptor), 110 µM glycine (glycine receptor), 
14 µM glutamate (GluR2), 11 µM GABA (GABAA("#$)), and 3 µM GABA 
(GABAA("#)). ND96 Ca2+ free buffer was used for the muscle type, ("4L9’A)3(#2)2, 
glycine, 5-HT3A, and GluR2 receptors. ND96 buffer was used for the GABAA and "7 
(T6’S) nAChRs. 
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